

SCORE Search Results Details for Application 10536880 and Search Result 20070125_140747_us-10-536-880a-27.rag.

Score Home Page Retrieve Application List SCORE System Overview SCORE FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125_140747_us-10-536-880a-27.rag.
start | next page

[Go Back to previous page](#)

GenCore version 6.2
Copyright (c) 1993 - 2007 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: January 28, 2007, 08:29:27 ; Search time 216 Seconds
(without alignments)
67.963 Million cell updates/sec

Title: US-10-536-880A-27
Perfect score: 150
Sequence: 1 HSDAIFDTSYRYRQLAVRRVLAALGRR 30

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2782304 seqs, 48933398 residues
Total number of hits satisfying chosen parameters: 2782304

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200701:
1: geneseqp1980s:
2: geneseqp1990s:
3: geneseqp2000s:
4: geneseqp2001s:
5: geneseqp2002s:
6: geneseqp2003as:
7: geneseqp2003bs:
8: geneseqp2004s:
9: geneseqp2005s:
10: geneseqp2006s:
11: geneseqp2007s:
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES
Result No. Score Match Length DB ID Description

pituitary adenylate cyclase activating polypeptide; PACAP;
vasoactive intestinal peptide; VIP; bronchus smooth muscular relaxation;
gastrointestinal-tract movement suppression;
optic-nerve degenerative disease; retina degenerative disease; toxicity;

1	150	100.0	30	8	ADP09604	ADP09604 PACAP/VIP
2	150	100.0	30	8	ADP09602	ADP09602 PACAP/VIP
3	150	100.0	30	8	ADP05662	ADP05662 Novel ant
4	150	100.0	30	8	ADP05660	ADP05660 Novel ant
5	150	100.0	30	8	ADT88475	ADT88475 Vasoactiv
6	150	100.0	30	8	ADT88477	ADT88477 Vasoactiv
7	150	100.0	30	8	ADP09605	ADP09605 PACAP/VIP
8	150	100.0	30	8	ADP05664	ADP05664 Novel ant
9	150	100.0	30	8	ADT88479	ADT88479 Vasoactiv
10	150	100.0	30	8	ADP09603	ADP09603 Pituitary
11	149	99.3	30	8	ADP09603	ADP09603 PACAP/VIP
12	149	99.3	30	8	ADP05661	ADP05661 Novel ant
13	149	99.3	30	8	ADT88476	ADT88476 Vasoactiv
14	149	99.3	30	8	ADP09606	ADP09606 PACAP/VIP
15	149	99.3	30	8	ADP05665	ADP05665 Novel ant
16	149	99.3	30	8	ADT88480	ADT88480 Vasoactiv
17	149	99.3	30	8	ADP09603	ADP09603 Pituitary
18	146	97.3	30	2	AAW10334	AAW10334 Synthetic
19	146	97.3	30	7	ADB61607	ADB61607 Conformat
20	146	97.3	30	8	ADF54730	ADF54730 Neurotoxi
21	146	97.3	30	8	ADP09581	ADP09581 PACAP/VIP
22	146	97.3	30	8	ADP43320	ADP43320 Retinal d
23	146	97.3	30	8	ADP05659	ADP05659 Novel ant
24	146	97.3	30	8	ADT88474	ADT88474 Vasoactiv
25	146	97.3	30	2	AAV05444	AAV05444 Bronchodi
26	146	97.3	30	5	ABB07022	ABB07022 Neurite i
27	146	97.3	30	8	ADP61594	ADP61594 Conformat
28	146	97.3	30	8	ADF54717	ADF54717 Neurotoxi
29	146	97.3	30	8	ADP09582	ADP09582 PACAP/VIP
30	146	97.3	30	8	ADP05663	ADP05663 Novel ant
31	146	97.3	30	8	ADT88478	ADT88478 Vasoactiv
32	145	96.7	30	9	ADB68825	ADB68825 Pituitary
33	145	96.7	30	9	ADB68832	ADB68832 Pituitary
34	144	96.0	30	9	ADB68826	ADB68826 Pituitary
35	143	95.3	30	2	AAW10335	AAW10335 Synthetic
36	143	95.3	30	2	AAW10333	AAW10333 Synthetic
37	143	95.3	30	4	AAW92124	AAW92124 Pituitary
38	143	95.3	30	5	ABB07020	ABB07020 Neurite i
39	143	95.3	30	7	ADB61606	ADB61606 Conformat
40	143	95.3	30	8	ADF54729	ADF54729 Neurotoxi
41	143	95.3	30	8	ADP43319	ADP43319 Retinal d
42	143	95.3	30	8	ADP05658	ADP05658 Novel ant
43	143	95.3	30	8	ADT88473	ADT88473 Vasoactiv
44	143	95.3	30	2	AAV05443	AAV05443 Bronchodi
45	143	95.3	30	5	ABB07021	ABB07021 Neurite i

ALIGNMENTS

RESULT 1
ADP09604
ID ADP09604 standard; peptide; 30 AA.
XX
AC ADP09604;
XX
XX

DT 26-AUG-2004 (first entry)
XX
DE PACAP/VIP derived peptide sequence SeqID 29.
XX
KW pituitary adenylate cyclase activating polypeptide; PACAP;
KW vasoactive intestinal peptide; VIP; bronchus smooth muscular relaxation;
KW gastrointestinal-tract movement suppression;
KW optic-nerve degenerative disease; retina degenerative disease; toxicity;

SCORE Search Results Details for Application 10536880 and Search Result 20070125_140749_us-10-536-880a-27.rup.

Score_Home_Page Retrieve Application List SCORE_System_Overview SCORE_FAQ Comments / Suggestions

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125_140749_us-10-536-880a-27.rup.

Start

Go Back to previous page

GenCore version 6.2
Copyright (c) 1993 - 2007 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: January 28, 2007, 08:33:06 ; Search time 345 Seconds
(without alignments)
93.228 Million cell updates/sec

Title: US-10-536-880A-27
Perfect score: 150
Sequence: 1 HSDAIFTDSYRRLAARVLAALGR 30

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 3281787 seqs, 1072124677 residues
Total number of hits satisfying chosen parameters: 3281787

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Uniprot_8.4.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	ID	Description
1	135	90.0	175	2 Q90X24_ICTPU	Q90x24 ictalurus p
2	135	90.0	195	1 PACA_CLAWA	P48144 clarias mac
3	134	89.3	38	1 PACA_URAJA	P81039 uranoscopus
4	134	89.3	38	2 Q75W89_9PERC	Q75w89 sebastiscus
5	134	89.3	170	2 Q4RH43_TETNG	Q4rh43 tetraodon n
6	132	88.0	38	2 Q75W94_HALRO	Q75w94 halocynthia
7	132	88.0	38	2 Q8IU37_SEPLE	Q8iu37 sepioteuthi
8	132	88.0	38	2 Q8IU36_PERAM	Q8iu36 periplaneta

SUMMARIES

9	132	88.0	38	2 Q8IU38_HYDMA	Q8iu38 hydra magni
10	132	88.0	38	2 Q8IU39_DUGJA	Q8iu39 dugesia jap
11	132	88.0	38	2 Q75W92_9PERC	Q75w92 stephanolep
12	132	88.0	38	2 Q75W87_ONCMY	Q75w87 oncorhynch
13	132	88.0	38	2 Q75W90_9TELE	Q75w90 sardinops m
14	132	88.0	38	2 Q8AY94_ACISC	Q8ay94 acipenser s
15	132	88.0	38	2 Q8AY95_TRAJP	Q8ay95 trachurus j
16	132	88.0	45	2 Q1Z2B9_PODSI	Q1z2b9 podarcis ei
17	132	88.0	62	2 Q53B14_BUNHO	Q53b14 bunopithecu
18	132	88.0	62	2 Q53B13_PONPY	Q53b13 pongo pygma
19	132	88.0	62	2 Q53B15_MACMU	Q53b15 macaca mula
20	132	88.0	62	2 Q53B12_9PRIM	Q53b12 gorilla gor
21	132	88.0	109	2 Q1ZY51_EABIT	Q1zy51 oryctolagus
22	132	88.0	138	2 Q98SP4_ONCMY	Q98sp4 oncorhynch
23	132	88.0	139	2 Q53BH1_HUMAN	Q53bh1 homo sapien
24	132	88.0	139	2 Q53BH0_PANTR	Q53bh0 pan troglod
25	132	88.0	161	2 Q51FLO_9PRIM	Q51flo saimiri bol
26	132	88.0	162	2 Q51FK8_PANTR	Q51fk8 pan troglod
27	132	88.0	162	2 Q5G7M0_MACFA	Q5g7m0 macaca fasc
28	132	88.0	170	2 Q8EJT8_MOUSE	Q8ejt8 mus musculu
29	132	88.0	171	1 PACA_RANRI	Q9u169 r glucagon
30	132	88.0	171	2 Q9PUF8_XENLA	Q9puf8 xenopus lae
31	132	88.0	173	1 PACA_ONCNE	P41585 oncorhynch
32	132	88.0	173	2 Q4RN19_TETNG	Q4rn19 tetraodon n
33	132	88.0	173	2 Q98SP5_ONCMY	Q98sp5 oncorhynch
34	132	88.0	175	1 PACA_MOUSE	Q70176 m pituitary
35	132	88.0	175	1 PACA_RAT	P13589 r pituitary
36	132	88.0	175	2 Q3UYH8_MOUSE	Q3uyh8 mus musculu
37	132	88.0	176	1 PACA_BOVIN	Q29w19 b pituitary
38	132	88.0	176	1 PACA_HUMAN	P18509 h pituitary
39	132	88.0	176	1 PACA_PIG	P41535 s pituitary
40	132	88.0	176	1 PACA_SHEEP	P16613 o pituitary
41	132	88.0	176	2 Q52LQ0_HUMAN	Q52lq0 homo sapien
42	130	86.7	38	2 Q75W88_9EUCA	Q75w88 eriocheir j
43	129	86.0	38	2 Q75W93_CYPCA	Q75w93 cyprinus ca
44	129	86.0	140	2 Q5XJ02_BRARE	Q5xj02 brachydanio
45	129	86.0	175	2 Q98TU3_BRARE	Q98tu3 brachydanio

ALIGNMENTS

RESULT 1
Q90X24_ICTPU PRELIMINARY; PRT; 175 AA.
AC Q90X24_ICTPU
DT 01-DEC-2001, integrated into UniProtKB/TrEMBL.
DT 07-FEB-2006, entry version 18.
DE Growth hormone-releasing hormone/pituitary adenylate cyclase-
DE activating polypeptide precursor.
OS Ictalurus punctatus (Channel catfish).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Siluriformes;
OC Ictaluridae; Ictalurus.
OX NCBI_TaxID=7998;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=21255738; PubMed=11356048; DOI=10.1006/gcen.2001.7651;
RA Small B.C., Noneman D.;
RT "Sequence and expression of a cDNA encoding both pituitary adenylate
RT cyclase activating polypeptide and growth hormone-releasing hormone-
RT like peptide in channel catfish (Ictalurus punctatus).";
RL Gen. Comp. Endocrinol. 122:354-363(2001).
CC -----

SCORE Search F

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10536880 and Search Result 20070125_140752_us-start

GenCore version 6.2

Copyright (c) 1993 - 2007 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: January 28, 2007, 08:36:42 ; Search time 39 Seconds
(without alignments)
74.013 Million cell updates/sec

Title: US-10-536-880A-27
Perfect score: 150
Sequence: 1 HSDAIFTDSYRRQLAVRRYLA AVLGR 30

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues 283416

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

```
Database : PIR_80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES						
Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	135	90.0	195	2	I50456	pituitary adenylat
2	132	88.0	38	2	A49165	pituitary adenylat
3	132	88.0	173	2	S34767	neuropeptides prec
4	132	88.0	175	2	A37786	pituitary adenylat
5	132	88.0	176	2	I84638	pituitary adenylat
6	132	88.0	176	2	A34044	pituitary adenylat
7	126	84.0	38	2	A61070	pituitary adenylat
8	119	79.3	27	2	A61071	pituitary adenylat
9	108.5	72.3	165	1	VRCH	vasoactive intesti
10	100.5	67.0	58	1	VRPG	vasoactive intesti
11	100.5	67.0	145	2	A60038	vasoactive intesti

12	100.5	67.0	170	1	VRHU	vasoactive intesti
13	100.5	67.0	170	1	VRRT	vasoactive intesti
14	100.5	67.0	170	2	A60037	vasoactive intesti
15	98	65.3	28	2	B60071	vasoactive intesti
16	98	65.3	28	2	A60304	vasoactive intesti
17	98	65.3	55	1	VRBO	vasoactive intesti
18	98	65.3	55	1	VRRE	vasoactive intesti
19	98	65.3	55	1	VRSH	vasoactive intesti
20	97	64.7	28	2	A60303	vasoactive intesti
21	95	63.3	25	2	JO0361	vasoactive intesti
22	95	63.3	55	1	VRGP	vasoactive intesti
23	94	62.7	28	2	A38232	vasoactive intesti
24	92	61.3	35	1	HWHG	extendin-2 - Gila m
25	76	50.7	38	1	HWHG	extendin-1 - Mexica
26	69	46.0	104	2	A32731	somatoliberin prec
27	64	42.7	44	1	RHBOS	somatoliberin - bo
28	64	42.7	44	1	RHPG	somatoliberin - pi
29	64	42.7	108	1	RPHUS	somatoliberin prec
30	60	40.0	131	1	SEPG	secretin precursor
31	58	38.7	133	2	JC2202	secretin - chicken
32	56	37.3	27	1	SECR	secretin precursor
33	56	37.3	134	2	A40959	secretin precursor
34	55	36.7	103	2	A41410	secretin precursor
35	53	35.3	127	2	E95298	conserved hypothet
36	52	34.7	289	2	B86955	conserved hypothet
37	52	34.7	324	2	S73000	hypothetical prote
38	50.5	33.7	957	2	T15976	hypothetical prote
39	50	33.3	31	2	S44472	glucagon G2 - Nort
40	49.5	33.0	168	2	AB0055	probable lipoprote
41	49	32.7	27	2	A27267	secretin - dog
42	49	32.7	421	2	C83147	gamma-glutamyl pho
43	49	32.7	636	2	T10569	probable serine/thr
44	49	32.7	772	2	C69990	transcription regu
45	48.5	32.3	252	2	F87259	hypoethetical prote

ALIGNMENTS

RESULT 1

accession: I50456
 title: pituitary adenylate cyclase activating polypeptide - Siamese catfish
 species: Clarias macrocephalus (Siamese catfish)
 date: 04-Sep-1997 #sequence_revision 04-Sep-1997 #text_change 09-Jul-2004
 accession: I50456
 author: R.McRory, J.E.; Parker, D.B.; Ngamwongchon, S.; Sherwood, N.M.
 mol. cell. endocrinol. 108, 169-177, 1995
 title: Sequence and expression of cDNA for pituitary adenylate cyclase activating polypeptide (PACAP) from the Siamese catfish, *Clarias macrocephalus*
 reference number: I50456; MUID:95278612; PMID:7758831
 accession: I50456
 status: preliminary; translated from GB/EMBL/DBJ
 molecule type: mRNA
 residues: 1-195 <MCH>
 cross-references: UNIPROT:P48144; UNIPAC:UP100001311D3; EMBL:X79078; PIDN:CAA55684.
 gene: PACAP
 superfamily: glucagon
 keywords: duplication

10/536880

=> file registry
FILE 'REGISTRY' ENTERED AT 12:18:30 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1
DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/resprogs.html>

=> d L8 rn cn sql nte lc kwic 1-30

L8 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868368-05-2 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-
leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-
leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)
SQL 10
NTE modified

type	location	description
terminal mod.	Arg-30	C-terminal amide

LC STN Files: CA, CAPLUS
NTE modified

type	location	description
terminal mod.	Arg-30	C-terminal amide

SEQ 1 HSDAIFTDSY SYRROLAVR RYLAALGRR YRQVRNR
HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868368-04-1 REGISTRY

10/536880

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-
L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-
arganyl-L-valyl-L-arginyl-L-asparaginy- (9CI) (CA INDEX NAME)
SQL 38
NTE modified

type	location	description
terminal mod.	Arg-38	C-terminal amide

LC STN Files: CA, CAPLUS
NTE modified

type	location	description
terminal mod.	Arg-38	C-terminal amide

SEQ 1 HSDAIFTDSY SYRROLAVR RYLAALGRR YRQVRNR
HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868368-03-0 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-
leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-
arganyl-L-valyl-L-arginyl-L-asparaginy- (9CI) (CA INDEX NAME)
SQL 38
NTE modified

type	location	description
terminal mod.	Arg-38	C-terminal amide

LC STN Files: CA, CAPLUS
NTE modified

type	location	description
terminal mod.	Arg-38	C-terminal amide

SEQ 1 HSDAIFTDSY SYRROLAVR RYLAALGRR YRQVRNR
HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868368-02-9 REGISTRY
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-

10/536880

valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30
NTE modified
type location description
terminal mod. His-1 N-acetyl
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAVFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868367-97-9 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAVFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

L8 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868367-91-3 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-glutamyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

10/536880

SQL 30
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAVFTENY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868367-70-8 REGISTRY
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30
NTE modified
type location description
terminal mod. His-1 N-acetyl
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAVFTDNY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 868367-65-1 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30
NTE modified

10/536880

type location description
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAFTDNY TRURQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 735801-36-2 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-arginyl-L-valyl-L-arginyl-L-asparaginy- (9CI) (CA INDEX NAME)

SQL 38

NTE modified

type location description
terminal mod. Arg-38 - C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-38 - C-terminal amide

SEQ 1 HSDAFTDSY SYRRQLAVR RYLAAILGRR YRQVRNR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 735801-35-1 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-arginyl-L-valyl-L-arginyl-L-asparaginy- (9CI) (CA INDEX NAME)

SQL 38

NTE modified

type location description

10/536880

type location description
terminal mod. Arg-38 - C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-38 - C-terminal amide

SEQ 1 HSDAIFTDSY SYRRQLAVR RYLAAILGRR YRQVRNR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 735801-33-9 REGISTRY

CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description
terminal mod. His-1 - N-acetyl
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAIFTDSY SYRRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 735801-32-8 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description

10/536880

terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SYRRLQAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2007 ACS ON STN

RN 735801-31-7 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified

type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SYRRLQAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2007 ACS ON STN

RN 735801-28-2 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -glutamyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS

10/536880

NTE modified
type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SYRRLQAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2007 ACS ON STN

RN 735801-25-9 REGISTRY
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description
terminal mod. His-1 N-acetyl
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified

type location description
terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SYRRLQAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2007 ACS ON STN

RN 735801-24-8 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SQL 30

NTE modified

type location description
terminal mod. Arg-30 C-terminal amide
LC STN Files: CA, CAPLUS
NTE modified

10/536880

type ----- location ----- description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAVFTDNY TELRQLAVR RYLAAILGRR
HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 73527-72-7 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 24: PN: WO2004048401 SEQID: 24 claimed sequence
CN 35: PN: JP2004315436 SEQID: 20 claimed sequence
SQL 30
NTE modified

type ----- location ----- description
terminal mod. Arg-30 - C-terminal amide

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified

type ----- location ----- description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAVFTANY TELRQLAVR RYLAAILGRR

HITS AT: 1-25

L8 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 702686-59-7 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyll-L-arginyl-L-valyl-L-arginyl-L-asparaginyll- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 31: PN: WO2004048401 SEQID: 31 claimed sequence
SQL 38
NTE modified

type ----- location ----- description
terminal mod. Arg-38 - C-terminal amide

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified

10/536880

type ----- location ----- description
terminal mod. Arg-38 - C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR YRQVRNR
HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 702686-58-6 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyll-L-arginyl-L-valyl-L-arginyl-L-asparaginyll- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 30: PN: WO2004048401 SEQID: 30 claimed protein
SQL 38
NTE modified

type ----- location ----- description
terminal mod. Arg-38 - C-terminal amide

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified

type ----- location ----- description
terminal mod. Arg-38 - C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR YRQVRNR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 702686-57-5 REGISTRY
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 29: PN: WO2004048401 SEQID: 29 claimed sequence
SQL 30
NTE modified

type ----- location ----- description
terminal mod. His-1 - N-acetyl
terminal mod. Arg-30 - C-terminal amide

10/536880

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 NTE modified
 type location description
 terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 702686-56-4 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 28: PN: W02004048401 SEQID: 28 claimed sequence

SQL 30

NTE modified

type location description
 terminal mod. Arg-30 C-terminal amide
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 NTE modified

type location description
 terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 702686-55-3 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 27: PN: W02004048401 SEQID: 27 claimed sequence

SQL 30

NTE modified

type location description

10/536880

terminal mod. Arg-30 C-terminal amide
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 NTE modified

type location description
 terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 702686-53-1 REGISTRY

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -glutamyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 22: PN: W02004048401 SEQID: 22 claimed protein

SQL 30

NTE modified

type location description
 terminal mod. Arg-30 C-terminal amide

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 NTE modified

type location description
 terminal mod. Arg-30 C-terminal amide

SEQ 1 HSDAIFTDSY SRYRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 702686-38-2 REGISTRY

CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 14: PN: W02004048401 SEQID: 14 claimed sequence

SQL 30

NTE modified

type location description

10/536880

terminal mod. His-1 - N-acetyl
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 702686-37-1 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 13: PN: WO2004048401 SEQID: 13 claimed protein
SQL 30
NTE modified

type location description
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 700368-96-3 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 26: PN: WO2004048401 SEQID: 26 claimed protein
SQL 30
NTE modified

13

10/536880

type location description
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

L8 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 700368-90-7 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 21: PN: WO2004048401 SEQID: 21 claimed protein
CN 33: PN: JP2004315436 SEQID: 17 claimed sequence
SQL 30
NTE modified

type location description
terminal mod. Arg-30 - C-terminal amide
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified
type location description
terminal mod. Arg-30 - C-terminal amide

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGRR

HITS AT: 1-25

L8 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN
RN 700368-87-2 REGISTRY
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 20: PN: WO2004048401 SEQID: 20 claimed protein
CN 32: PN: JP2004315436 SEQID: 16 claimed sequence
SQL 29
NTE modified

14

10/536880

type ----- location ----- description -----
terminal mod. Arg-29 - C-terminal amide -----
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL -----
NTE modified -----
type ----- location ----- description -----
terminal mod. Arg-29 - C-terminal amide -----

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGR

HITS AT: 1-25

L8 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 700368-85-0 REGISTRY

CN L-lysineamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 19: PN: W02004048401 SEQID: 19 claimed protein

CN 31: PN: JP2004315436 SEQID: 15 claimed sequence

SQL 29

NTE modified

type ----- location ----- description -----
terminal mod. Lys-29 - C-terminal amide -----
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL -----
NTE modified -----
type ----- location ----- description -----
terminal mod. Lys-29 - C-terminal amide -----

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILGK

HITS AT: 1-25

L8 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2007 ACS on STN

RN 700368-83-8 REGISTRY

CN Glycinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 18: PN: W02004048401 SEQID: 18 claimed protein

CN 30: PN: JP2004315436 SEQID: 14 claimed sequence

SQL 28

NTE modified

type ----- location ----- description -----

10/536880

terminal mod. Gly-28 - C-terminal amide -----
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL -----
NTE modified -----
type ----- location ----- description -----
terminal mod. Gly-28 - C-terminal amide -----

SEQ 1 HSDAFTDNY TRLRQLAVR RYLAAILG

HITS AT: 1-25

10/536880

=> file caplus
FILE 'CAPLUS' ENTERED AT 12:21:11 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBJ' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L24

L19 2952 SEA FILE=CAPLUS ABB=ON PLU=ON MATSUMOTO A7/AU
L20 4255 SEA FILE=CAPLUS ABB=ON PLU=ON ENDO K7/AU
L21 118 SEA FILE=CAPLUS ABB=ON PLU=ON OMOUE S7/AU
L22 13 SEA FILE=CAPLUS ABB=ON PLU=ON L19 AND (L20 OR L21)
L23 16 SEA FILE=CAPLUS ABB=ON PLU=ON L20 AND L21
L24 23 SEA FILE=CAPLUS ABB=ON PLU=ON (L22 OR L23)


=> d stat que L25

L3 113096 SEA FILE=REGISTRY ABB=ON PLU=ON AMI7/NTE
L6 54 SEA FILE=REGISTRY ABB=ON PLU=ON HSDA[IV]FT [DEA] [SND]Y[ST]R [YL] [RQQLAVRYLAA/SQSP]
L8 30 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND L3
L9 4 SEA FILE=CAPLUS ABB=ON PLU=ON L8
L10 STR

* STRUCTURE-DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L10.str

10/536880



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46 47 48
49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
70 71 72
73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 97 98 99
100 101 104

ring nodes :

91 92 93 94 95 96

chain bonds :

1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69
17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 31-98 32-51
33-34 33-99
34-52 35-36 35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-
58 58-61
59-61 60-61 62-63 63-64 64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73
77-78 78-79 79-80
80-81 81-82 81-83 84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97

ring bonds :

91-95 91-92 92-93 93-94 94-96 95-96

exact/norm bonds :

1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69
17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 32-51 33-34
34-52 35-36
36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-58 58-61 59-61 60-61
62-63 63-64
64-65 65-68
66-68 67-68 69-70 70-71 71-72 71-73 77-78 78-79 79-80 80-81
81-82 81-83
84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97

10/536880

exact bonds :
31-98 33-99 35-100
normalized bonds :
91-95 91-92 92-93 93-94 94-96 95-96

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS
40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS
48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS
58:CLASS 59:CLASS
60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:CLASS 66:CLASS 67:CLASS
68:CLASS 69:CLASS
70:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:CLASS 77:CLASS
78:CLASS 79:CLASS
80:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS 87:CLASS
88:CLASS 89:CLASS
90:CLASS 91:Atom 92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS
99:CLASS
100:CLASS 101:CLASS 104:CLASS

L15 11 SEA FILE-REGISTRY SSS FUL L10
L16 9 SEA FILE-CAPLUS ABB-ON PLU-ON L15
L19 2952 SEA FILE-CAPLUS ABB-ON PLU-ON MATSUMOTO A7/AU
L20 4255 SEA FILE-CAPLUS ABB-ON PLU-ON ENDO K2/AU
L21 118 SEA FILE-CAPLUS ABB-ON PLU-ON ONOUE S7/AU
L25 3 SEA FILE-CAPLUS ABB-ON PLU-ON (L19 OR L20 OR L21) AND (L16 OR L9)

=> s L24-L25
L32 25 (L24 OR L25)

=> file medline embase biosis

FILE 'MEDLINE' ENTERED AT 12:21:41 ON 30 JAN 2007

FILE 'EMBASE' ENTERED AT 12:21:41 ON 30 JAN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:21:41 ON 30 JAN 2007
Copyright (c) 2007 The Thomson Corporation

=> d stat que L30

L19 2952 SEA FILE-CAPLUS ABB-ON PLU-ON MATSUMOTO A7/AU
L20 4255 SEA FILE-CAPLUS ABB-ON PLU-ON ENDO K2/AU
L21 118 SEA FILE-CAPLUS ABB-ON PLU-ON ONOUE S7/AU
L22 13 SEA FILE-CAPLUS ABB-ON PLU-ON L19 AND (L20 OR L21)
L23 16 SEA FILE-CAPLUS ABB-ON PLU-ON L20 AND L21
L24 23 SEA FILE-CAPLUS ABB-ON PLU-ON (L22 OR L23)
L30 42 SEA L24

19

10/536880

=> file toxcenter
FILE 'TOXCENTER' ENTERED AT 12:21:53 ON 30 JAN 2007
Copyright (c) 2007 ACS

FILE COVERS 1907 TO 23 JAN 2007 (20070123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MESH terms and See HELP ROAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MESH 2007 vocabulary.

=> d stat que L29
L19 2952 SEA FILE-CAPLUS ABB-ON PLU-ON MATSUMOTO A7/AU
L20 4255 SEA FILE-CAPLUS ABB-ON PLU-ON ENDO K2/AU
L21 118 SEA FILE-CAPLUS ABB-ON PLU-ON ONOUE S7/AU
L22 13 SEA FILE-CAPLUS ABB-ON PLU-ON L19 AND (L20 OR L21)
L23 16 SEA FILE-CAPLUS ABB-ON PLU-ON L20 AND L21
L29 20 SEA FILE-TOXCENTER ABB-ON PLU-ON (L22 OR L23)

=> dup rem L32 L30 L29

FILE 'CAPLUS' ENTERED AT 12:22:17 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:22:17 ON 30 JAN 2007

FILE 'EMBASE' ENTERED AT 12:22:17 ON 30 JAN 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:22:17 ON 30 JAN 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 12:22:17 ON 30 JAN 2007
COPYRIGHT (C) 2007 ACS

PROCESSING COMPLETED FOR L32

PROCESSING COMPLETED FOR L30

PROCESSING COMPLETED FOR L29

L33 32 DUP REM L32 L30 L29 (55 DUPLICATES REMOVED)

ANSWERS '1-25' FROM FILE CAPLUS

ANSWERS '26' FROM FILE MEDLINE

ANSWERS '27-32' FROM FILE BIOSIS

=> d ibib abs hitind hitstr L33 1-25; d iall L33 26-32

L33 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 1

ACCESSION NUMBER: 2006:485110 CAPLUS Full-text

DOCUMENT NUMBER: 145:109921

TITLE:
Development of dry powder inhalation system of novel
vasoactive intestinal peptide (VIP) analogue for
pulmonary administration
Ohmori, Yuki; Onoue, Satomi; Endo,

20

10/536880

Kosuke; Matsumoto, Asami; Uchida,
Shinya; Yamada, Shizuo
Department of Pharmacokinetics and Pharmacodynamics
and COE Program in the 21st Century, School of
Pharmaceutical Sciences, University of Shizuoka,
Suruga-ku, Shizuoka, 422-8526, Japan
Life Sciences (2006), 79(2), 138-143
CODEN: LIPSAK; ISSN: 0024-3205
Elsevier B.V.
Journal
English
AB Vasoactive intestinal peptide (VIP) exerts a relaxing action on tracheal
smooth muscle which is mediated through interaction with VIP receptors. The
deficiency of VIP in the airways has been implicated in the pathogenesis of
asthma. Thus, the administration of VIP may be useful for the therapy of
pulmonary diseases. However, the therapeutic application of VIP is largely
limited by its rapid degradation in addition to the systemic adverse effects
due to the wide distribution of VIP receptors. To overcome these problems, we
succeeded to synthesize a novel VIP derivative of VIP, IR15, 20, 21, L17-VIP-
GRR (IK12532), and to prepare its dry powder for the topical administration
to the lung. The physicochem. properties of dry powder were evaluated by
laser diffraction and cascade impactor. The laser diffraction anal. indicated
that the carrier and fine particles had median diameter of 65.6 and 4.5 µm,
resp., and the air flow at the pressure of 0.15 MPa or higher resulted in the
high dispersion and significant separation of fine particle containing peptide
from the carrier mol. The cascade impactor anal. clearly showed the high
emission of dry powder from capsule and the deposition of peptide on stages 3
of the cascade impactor. The intratracheal administration of dry powder
inhaler (DPI) of VIP or IK12532 brought about a significant decrease of
maximal number of binding sites (Bmax) for [125I]VIP in anterior and posterior
lobes of rat right lung, suggesting a significant occupancy of lung VIP
receptors. This effect by IK12532-DPI compared with VIP-DPI lasted for a
longer period. Thus, IK12532-DPI may be a pharmacol. useful drug delivery
system for the VIP therapy of pulmonary diseases such as asthma.

CC 63-5 (Pharmaceuticals)
REFERENCE COUNT: 36
L33 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:48083 CAPLUS Full-text
DOCUMENT NUMBER: 143:83291
TITLE: Erythritol-based dry powder of glucagon for pulmonary
administration
AUTHOR(S): Endo, Kosuke; Amikawa, Satoko;
Matsumoto, Asami; Sahashi, Norio; Onoue,
Satomi
CORPORATE SOURCE: Pharmaceutical Division, Ito Life Sciences Inc.,
Moriya, Ibaraki, 302-0104, Japan
SOURCE: International Journal of Pharmaceutics (2005),
290(1-2), 63-71
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Glucagon, a key regulatory element of glycogen metabolism, is known to be
effective in the clin. treatment of hypoglycemia and the maintenance of normal
circulating glucose levels in patients with total pancreatectomy, however the
clin. use of this gut hormone has been restricted to parenteral
administration. In this investigation, we prepared dry powder dosage forms of
glucagon, which were formulated by mixing micronized glucagon particles and

10/536880

excipients with larger carrier particles. To achieve alveolar deposition for
subsequent systemic absorption, a dry powder inhalant (DPI) of glucagon was
size-reduced to a mass median diameter between 1 and 6 µm, as measured by
laser diffraction anal. The use of erythritol as both excipient and carrier
in DPI of glucagon resulted in high and reproducible flowability and
dispersibility of the powder mixts., and therefore it provided a low dosing of
the active substances. Distinct transpulmonary absorption of glucagon was
confirmed after intratracheal administration of the glucagon dry powder to
anesthetized rats, as evidenced by the increase in the blood glucagon and
blood sugar levels. These results suggested the usefulness of an erythritol-
based powder form of glucagon for systemic administration.

CC 63-5 (Pharmaceuticals)
REFERENCE COUNT: 30
L33 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:467910 CAPLUS Full-text
DOCUMENT NUMBER: 141:33832
TITLE: Peptides and medicinal compositions containing the
same
INVENTOR(S): Onoue, Satomi; Endo, Kosuke;
Matsumoto, Asami
PATENT ASSIGNEE(S): Itoham Foods Inc., Japan
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/048401	A1	20040610	WO 2003-JP14924	20031121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507616	A1	20040610	CA 2003-2507616	20031121
AU 2003284428	A1	20040618	AU 2003-284428	20031121
EP 1571155	A1	20050907	EP 2003-775859	20031121
R: AE, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1732182	A	20060208	CN 2003-80107764	20031121
US 2006276384	A1	20061207	US 2005-536880	20050527
PRIORITY APPLN. INFO.:			JP 2002-344523	20021127
			WO 2003-JP14924	W 20031121

AB Disclosed is a medicinal composition containing, as the active ingredient, a peptide derived from a PACAP peptide or a VIP peptide or a pharmaceutically acceptable salt thereof. Thus, a PACAP/VIP derivative the tautomerization of which in the state of a solution is inhibited and thus which can be clin. employed over a long period of time is provided. These peptides are efficacious in ameliorating symptoms of diseases such as regressive neurodegenerative diseases, erectile dysfunction and bronchial asthma. A

peptide His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Arg-Gln-Leu-Ala-Val-Arg-Arg-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Gly-Arg-Arg-NH₂ (I) was prepared, and its stability in water with various pH was tested. An inhalant powder containing I with erythritol carrier was formulated.

IC CM C07K014-00

ICS A61K038-16; A61P001-12; A61P007-02; A61P009-00; A61P009-10; A61P011-08; A61P013-12; A61P015-10; A61P017-14; A61P025-00; A61P025-28; A61P027-02

CC 1-12 (Pharmacology)

Section cross-reference (s): 63

IT 40077-57-4P. Vasoactive intestinal octacosapeptide (swine) 127317-03-7P
134582-08-4P 475083-13-7P 700368-76-9P 700368-79-2P 700368-81-6P

700368-83-8P 700368-85-0P 700368-87-2P

700368-90-7P 700368-92-9P 700368-94-1P 700368-96-3P

700368-98-5P 700369-00-2P 700369-02-4P 702686-30-4P 702686-31-5P

702686-33-7P 702686-36-0P 702686-37-1P 702686-38-2P

702686-42-8P 702686-49-5P 702686-52-0P 702686-53-1P

702686-55-3P 702686-56-4P 702686-57-5P

702686-58-6P 702686-59-7P 735327-72-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(peptides containing PACAP/VIP derivs. and medicinal compns.)

IT 700368-83-8P 700368-85-0P 700368-87-2P

700368-90-7P 700368-96-3P 702686-37-1P

702686-38-2P 702686-53-1P 702686-55-3P

702686-56-4P 702686-57-5P 702686-58-6P

702686-59-7P 735327-72-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(peptides containing PACAP/VIP derivs. and medicinal compns.)

RN 700368-83-8 CAPIUS

CN Glycinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-





phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-

threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-

alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-alanyl-L-alanyl-L-


isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/536880


PAGE 1-E




RN 700368-85-0 CAPLUS
 CN L-Lysinamide, L-histidyl-L-seeryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyll-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




10/536880


PAGE 1-C



PAGE 1-D







PAGE 1-E



RN 700368-87-2 CAPLUS
 CN L-Argininamide, L-histidyl-L-seeryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyll-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 700368-90-7 CAPLUS

L-Arginamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-Arginamide, L-threonyl-L- α -aspartyl-L-asparagyl-L-tyrosyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arganyl-L-leucyl-L-arganyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arganyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.











RN 700368-96-3 CAPLUS

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 702686-37-1 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-

isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-38-2 CAPLUS
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-53-1 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -glutamyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-55-3 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-56-4 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-57-5 CAPLUS
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 702686-58-6 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyll-L-arginyl-L-valyl-L-arginyl-L-asparaginyll- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 702686-59-7 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminyll-L-

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 735327-72-7 CAPLUS
 CN L-Argininamide, L-histidyl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-E



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L33 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2004:371854 CAPLUS Full-text

DOCUMENT NUMBER: 140:418294

TITLE: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells

AUTHOR(S): Oonue, Satomi; Ohmori, Yuki; Endo,


Kosuke; Yamada, Shizuo; Kimura, Ryohei; Yajima, Takehiko

CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., Ibaraki, Japan


SOURCE: European Journal of Biochemistry (2004), 271(9), 1757-1767

PUBLISHER: CODEN: EJBICAI; ISSN: 0014-2956 Blackwell Publishing Ltd.

PAGE 1-B



PAGE 1-C



DOCUMENT TYPE: Journal
LANGUAGE: English

AB Chronic obstructive pulmonary disease is a major clin. disorder usually associated with cigarette smoking. A central feature of chronic obstructive pulmonary disease is inflammation coexisting with an abnormal protease/antiprotease balance, leading to apoptosis and elastolysis. In an *in vitro* study of rat lung alveolar L2 cells, cigarette smoke extract (CSE) induced apoptotic cell death. Exposure of L2 cells to CSE at a concentration of 0.25% resulted in a 50% increase of caspase-3 and matrix metalloproteinase (MMP) activities. Specific inhibitors for caspases and MMPs attenuated the cytotoxicity of CSE. RT-PCR amplification identified VPAC2 receptors in L2 cells. A radioligand-binding assay with 125I-labeled vasoactive intestinal peptide (VIP) found high affinity and saturable 125I-labeled VIP-binding sites in L2 cells. VIP and pituitary adenylate cyclase-activating polypeptide (PACAP27) were approx. equipotent for both VIP receptor binding and stimulation of cAMP production in L2 cells. Both neuropeptides, at concns. higher than 10⁻¹³ M, produced a concentration-dependent inhibition of CSE-induced cell death in L2 cells. VIP, at 10⁻⁷ M, reduced CSE-stimulated MMP activity and caspase-3 activation. The present study has shown that VIP and PACAP27 significantly attenuate the cytotoxicity of CSE through the activation of VPAC2 receptor, and the protective effect of VIP may partly be the result of a reduction in the CSE-induced stimulation of MMPs and caspases.

CC 2-6 (Mammalian Hormones)

Section cross-reference (s): 4

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2004:35149 CAPLUS Full-text

DOCUMENT NUMBER: 140:297670

TITLE: Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine

AUTHOR(S):

Onoue, Satomi; Ohmori, Yuki; Matsumoto, Asami; Yamada, Shizuo; Kimura, Ryohei; Yajima, Takehiko; Kashimoto, Kazuhisa

CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., Moriya, Ibaraki, 302-0104, Japan

SOURCE: Life Sciences (2004), 74(12), 1465-1477

CODEN: LIFSAC; ISSN: 0024-3205

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In order to develop potent-shortened analogs of vasoactive intestinal peptide (VIP), the structure-activity relationship of C-terminally truncated analogs of VIP was investigated by examining the binding activity to rat lung VIP receptors and relaxation of smooth muscle in isolated mouse stomach. VIP(1-27) showed VIP receptor binding activity comparable to that of VIP but the activity of VIP(1-26) was reduced to one-third of VIP. The receptor binding activity of VIP(1-26) to VIP(1-23) was reduced in proportion to the decrease in amino acid residues. There was a significant correlation between the number of amino acid residues and VIP receptor binding activities of VIP and its C-terminally truncated analogs. VIP(1-22) and VIP(1-21) exhibited little binding activity even at high concns., suggesting the requisite of 23 amino acid residues as the minimal essential sequence for the conservation of VIP receptor binding activity. The chemical modification of VIP(1-23) generated a potent analog, [Arg15, 20, 21, Leu17]-VIP(1-23), that displayed a 22-fold higher receptor binding activity and 1.6-fold more potent relaxation of mouse stomach than VIP(1-23) did. In conclusion, it was shown that [Arg15, 20, 21,

Leu17]-VIP(1-23) could be a relatively potent and stable agonist of VIP receptors. The present study has provided further insight into the structure-activity relationship of VIP to generate novel shortened VIP analogs having a high affinity to VIP receptors and potent pharmacol. activity.

CC 2-2 (Mammalian Hormones)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:78836 CAPLUS Full-text

DOCUMENT NUMBER: 140:264668

TITLE: α -Helical structure in the C-terminus of

vasoactive intestinal peptide: functional and structural consequences

Onoue, Satomi; Matsumoto, Asami;

Nagano, Yumiko; Ohshima, Keiichi; Ohmori, Yuki; Yamada, Shizuo; Kimura, Ryohei; Yajima, Takehiko; Kashimoto, Kazuhisa

CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., Moriya, Ibaraki, 302-0104, Japan

SOURCE: European Journal of Pharmacology (2004), 485(1-3),

307-316

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The conformational properties of vasoactive intestinal peptide (VIP) include the N-terminal randomized structure and the C-terminal long α -helical structure. The authors have previously observed that the N-terminal random coil structure plays a crucial role in the receptor-selectivity. Here, to clarify how the formation of the α -helix plays a role in its biol. functions, the authors chemical synthesized VIP analogs modified at the C-terminus, mid-chain, and N-terminus of the α -helical region, and evaluated the relationship between their α -helical contents and their biol. activities including relaxant effects on murine stomach and receptor-binding activities. VIP and VIP-(1-27) showed equipotent biol. activities with 48% and 50% α -helical content, resp., each of which corresponds to 14 amino acid residues. VIP-(1-26) was 10% and threefold less potent in relaxant and binding activities, resp., compared with VIP, and its 49% α -helical content resulted in 13 residues involved in the α -helix. Further truncation from 25 to 21 resulted in decrease in the α -helical content from 43% to 29%, corresponding residues from 11 to 6, the relaxant activity from 72% to 4%, and the affinity to the membrane from 60-fold to over 104-fold less potency. In addition, disruption of the mid-chain and the N-terminus in the α -helical stretch by oxidation of Met17 and deletion of Thr11 also inhibited biol. activities. These findings suggest that the presence of α -helical structure forming in 14 amino acid residues between position 10 and 23 in VIP is essential to its biol. functions and the C-terminal amino acid residues between position 24 and 27 are requisite for this α -helical formation.

CC 2-2 (Mammalian Hormones)

REFERENCE COUNT: 53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:917676 CAPLUS Full-text

DOCUMENT NUMBER: 141:389080

TITLE: Pharmacological effects and lung-binding

characteristics of a novel VIP analogue, [R15, 20, 21,

10/536880

AUTHOR(S): L17]-VIP-GRR (IK312532)
Ohnori, Yuki; Maruyama, Shuji; Kimura, Ryohei;
Onoue, Satoshi; Matsumoto, Asami;
Endo, Kosuke; Iwanaga, Toshihiko; Kashimoto,
Kazuhiisa; Yamada, Shizuo
CORPORATE SOURCE: School of Pharmaceutical Sciences, Department of
Biopharmaceutical Sciences and COE Program in the 21st
Century, University of Shizuoka, Shizuoka, 422-8526,
Japan
SOURCE: Regulatory Peptides (2004), 123(1-3), 201-207
CODEN: REPPDY; ISSN: 0167-0115
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A novel VIP derivative, [R15, 20, 21, L17]-VIP-GRR (IK 312532), relaxed
potently the carbachol-induced contraction of guinea pig isolated trachea with
longer duration than that induced by VIP. IK 312532 competed with [125I]VIP
for the binding sites in the rat lung in a concentration-dependent manner.
There was considerable decrease in specific [125I]VIP binding in each lobe of
right and left lung 0.5 h after the intratracheal administration of IK 312532
(50 µg/rat) as dry powder inhaler (DPI). Rosenthal anal. revealed that the
administration of IK 312532 (50 and 100 µg/rat)-DPI brought about a
significant decrease of maximal number of binding sites (Bmax) for specific
[125I]VIP binding in anterior and posterior lobes of rat right lung,
suggesting a significant occupancy of lung VIP receptors. This effect by IK
312532 in the posterior lobe of the right lung was dose-dependent and lasted
until at least 2 h after the intratracheal administration. Furthermore, the
antigen-evoked infiltration of granulocytes in the rat bronchiolar mucosa was
markedly suppressed by the intratracheal administration of IK 312532 (50
µg/rat)-DPI. In conclusion, the present study has shown that IK 312532
exhibits long-lasting relaxation of tracheal smooth muscles and that the
intratracheal administration of this peptide exerts a significant occupancy of
lung VIP receptors as well as a suppression of the antigen-evoked infiltration
of granulocytes in the bronchiolar mucosa. Thus, the formulation of IK 312532
as DPI may be a pharmacol. useful drug delivery system for the therapy of
pulmonary diseases such as asthma.
CC 2-6 (Mammalian Hormones)
REFERENCE COUNT: 34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 8
ACCESSION NUMBER: 2004:91675 CAPLUS Full-text
DOCUMENT NUMBER: 141:389079
TITLE: Long-acting analogue of vasoactive intestinal peptide,
[R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat
alveolar L2 cells from the cytotoxicity of cigarette
smoke
AUTHOR(S): Onoue, Satoshi; Endo, Kosuke;
Ohnori, Yuki; Yamada, Shizuo; Kimura, Ryohei; Yajima,
Takehiko; Kashimoto, Kazuhisa
CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., Moriya,
Ibaraki, 302-0104, Japan
SOURCE: Regulatory Peptides (2004), 123(1-3), 193-199
CODEN: REPPDY; ISSN: 0167-0115
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating
polypeptide (PACAP) act as neurotransmitters in numerous biol. responses. We

37

10/536880

previously reported that the replacement of Lys by Arg, and Met by Leu in VIP
(IK 312532; [Arg15, 20, 21, Leu17]-VIP) resulted in a significant improvement
in metabolic stability and biol. activity. In the present study, we
investigated the effect of VIP and its related peptides including long-acting
VIP derivative (IK 312532) and PACAP27 on the cytotoxicity of cigarette smoke
extract (CSE), a causative factor of chronic obstructive pulmonary disease
(COPD), in rat alveolar L2 cells. RT-PCR displayed the dominant expression of
mRNA for the VIP-specific VPAC2 receptor in L2 cells, and VIP and the related
peptides showed the specific binding activity and potent stimulation of
adenylate cyclase. CSE at a concentration of 0.1% or higher induced
significant apoptotic death of L2 cells. Interestingly, the addition of
neuropeptides at a concentration of 10-11 M or higher in L2 cells with CSE
(0.25%) resulted in significant attenuation of cell death with the
deactivation of CSE-evoked caspase-3 activity. IK 312532 was much stable
against the enzymic digestion compared to VIP, and the protective effect of IK
312532 was 1.6-fold higher than that of VIP. Taken together with our previous
report showing that IK 312532 has long-acting relaxant activity in the lung,
IK 312532 may be a potential candidate for drug treatment of asthma and COPD.
CC 2-6 (Mammalian Hormones)
Section cross-reference(s): 4
REFERENCE COUNT: 30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 9
ACCESSION NUMBER: 2003:449565 CAPLUS Full-text
DOCUMENT NUMBER: 139:209524
TITLE: Misfolding of therapeutic peptides and the
cytotoxicity of peptide fibrils
AUTHOR(S): Onoue, Satoshi; Onshima, Keiichi; Endo,
Kosuke; Yajima, Takehiko; Kashimoto, Kazuhisa
CORPORATE SOURCE: Health Science Division, Itoham Food Inc., Moriya,
Ibaraki, 302-0104, Japan
SOURCE: Peptide Science (2003), Volume Date 2002, 39th,
393-396
CODEN: PSTCQ; ISSN: 1344-7661
PUBLISHER: Japanese Peptide Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Misfolding of peptides/proteins including β -amyloid, prion protein, and amylin
generates the amyloidogenic isoforms with the abundant of β -sheet structure,
and these fibrils are causative agents for some neurodegenerative disorders.
In addition to these toxic agents, some therapeutic peptides also displayed
the conformational changes into β -sheet rich fibrils in a time-dependent
manner. Here, we demonstrated that incubation of human glucagon and salmon
calcitonin at the concentration of 5.0 mg/mL or higher resulted in a
significant increase of fibril generation, and these fibrils are toxic to
neuron-like PC12 cells and fibroblast NIH-3T3 cells via activation of an
apoptotic enzyme caspase-3.
CC 6-3 (General Biochemistry)
Section cross-reference(s): 1
REFERENCE COUNT: 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 10
ACCESSION NUMBER: 2003:449537 CAPLUS Full-text
DOCUMENT NUMBER: 139:240629
TITLE: Development of a new vasoactive intestinal peptide
analogue and its topical administration system, dry
powder inhalation

38

10/536880

AUTHOR(S): Endo, Kosuke; Onoue, Satomi; Amikawa, Satoko; Matsumoto, Asami; Ohmori, Yuki; Yamada, Shizuo; Kimura, Ryohei; Kashimoto, Kazuhisa

CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., Moriya, Ibaraki, 302-0104, Japan

SOURCE: Peptide Science (2003), Volume Date 2002, 39th, 301-304

PUBLISHER: CODEN: PSCIFQ; ISSN: 1344-7661

DOCUMENT TYPE: Japanese Peptide Society

LANGUAGE: English

AB Vasoactive intestinal peptide (VIP) has been considered as a candidate of novel drugs to treat asthma, since it was confirmed that VIP neuron was involved in the regulation of bronchodilation in human lung. Although it is well-established that VIP is effective in several types of bronchoconstriction in vivo and in vitro, there are serious problems including the stability of VIP against enzymic digestion, its dosage form, and the undesired side effect due to the wide-distribution of VIP preferring receptors. Here, we have synthesized the stabilized VIP analog, and topical administration method has been developed for the respiratory systems such as trachea, bronchus and lung.

CC 2-6 (Mammalian Hormones)

REFERENCE COUNT: 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 12

ACCESSION NUMBER: 2002:636020 CAPLUS Full-text

DOCUMENT NUMBER: 138:19718

TITLE: The neuropeptide PACAP attenuates β -amyloid (1-42)-induced toxicity in PC12 cells

AUTHOR(S): Onoue, Satomi; Endo, Kosuke; Ohshima, Keiichi; Yajima, Takehiko; Kashimoto, Kazuhisa

CORPORATE SOURCE: Health Science Division, Central Research Institute Itoham Foods Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki, 302-0104, Japan

SOURCE: Peptides (New York, NY, United States) (2002), 23(8), 1471-1478

PUBLISHER: CODEN: PPTD5; ISSN: 0196-9781

DOCUMENT TYPE: Elsevier Science Inc.

LANGUAGE: English

AB Pituitary adenylylate cyclase activating polypeptide (PACAP) modulates neurotransmission in the central and peripheral nervous systems. In vitro and in vivo studies have shown the protective effects of PACAP against neuronal damage induced by ischemia and agonists of NMDA-type glutamate receptors. Here, we demonstrated that PACAP also protected against neuronal toxicity induced by β -amyloid (A β) peptide, aggregation of which is a causative factor for Alzheimer's disease. PACAP (10-9 M) rescued 80% of decreased cell viability and 50% of elevated caspase-3 activity that resulted from exposure of PC12 cells to A β . PACAP was at least 104-fold more effective than other neuropeptides including vasoactive intestinal peptide (VIP) and humanin, which correlated with the level of cAMP accumulation. Thus, our results suggested that PACAP attenuates A β -induced cell death in PC12 cells through an increase in cAMP and that caspase-3 deactivation by PACAP is involved in the signaling pathway for this neuroprotection.

CC 2-5 (Mammalian Hormones)

REFERENCE COUNT: 46

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

39

10/536880

L33 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 13

ACCESSION NUMBER: 2004:28522 CAPLUS Full-text

DOCUMENT NUMBER: 141:33987

TITLE: Pituitary adenylylate cyclase-activating polypeptide inhibited the β -amyloid-induced neurotoxicity and activation of caspase-3

AUTHOR(S): Endo, Kosuke; Onoue, Satomi; Ohshima, Keiichi; Yajima, Takehiko; Kashimoto, Kazuhisa

CORPORATE SOURCE: Itoham Foods Inc., Moriya, Ibaraki, 302-0104, Japan

SOURCE: Peptides 2002, Proceedings of the European Peptide Symposium, 27th, Sorrento, Italy, Aug. 31-Sept. 6, 2002 (2002), 472-473. Editor(s): Benedetti, Ettore; Pedone, Carlo. Edizioni Ziino: Castellammare di Stabia, Italy.

DOCUMENT TYPE: CODEN: 69EYXG; ISBN: 88-900948-1-8

LANGUAGE: English

AB Pituitary adenylylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are closely related neuropeptides in terms of sequence, solution structure and physiological functions. The effect of PACAP/VIP on β -amyloid (A β)-induced neurotoxicity in rat pheochromocytoma cells (PC12 cells) in vitro was evaluated. PACAP27 (10-15-10-9 M) and VIP (10-9-10-7 M) showed significant neuroprotective effects against the A β -induced neuronal damage. The results indicated that PACAP27-induced neuroprotection against A β -induced cell death is mediated via the cAMP-dependent signaling pathway and also caspase-3 deactivation.

CC 2-5 (Mammalian Hormones)

REFERENCE COUNT: 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 14

ACCESSION NUMBER: 2002:381009 CAPLUS Full-text

DOCUMENT NUMBER: 137:104139

TITLE: Pituitary adenylylate cyclase activating polypeptide regulates the basal production of nitric oxide in PC12 cells

AUTHOR(S): Onoue, Satomi; Endo, Kosuke; Yajima, Takehiko; Kashimoto, Kazuhisa

CORPORATE SOURCE: Health Science Division, Itoham Foods Inc., 1-2, Kubogaoka, Moriya, Ibaraki, 302-0104, Japan

SOURCE: Life Sciences (2002), 71(2), 205-214

PUBLISHER: CODEN: LIFSAB; ISSN: 0024-3205

DOCUMENT TYPE: Elsevier Science Inc.

LANGUAGE: English

AB We investigated the neuronal role of VIP and PACAP in NO production in PC12 cells. PACAP decreased NO production in a dose-dependent manner, and the activators of protein kinase A and C also inhibited the NO production in PC12 cells. RT-PCR expts. demonstrated that PC12 cells constitutively express the mRNAs for neuronal NOS and the PACAP-specific (PAC1) receptor, and we concluded that PACAP plays an important role in the regulation of nNOS activity through PAC1 receptor in PC12 cells.

CC 2-10 (Mammalian Hormones)

REFERENCE COUNT: 40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN DUPLICATE 15

40

10/536880

2003:48492 CAPLUS Full-text
138:231878
Differences in biological activity between PACAP27 and VIP in PC12 cells depend on their N-terminal structures
Onoue, Satomi; Nagano, Yumiko; Endo, Kouke; Yajima, Takehiko; Kashimoto, Kazuhisa 302-0104, Japan
Pharmacology Reviews and Communications (2002), 12(4), 205-213
CODEN: PHRCF6; ISSN: 1028-8945
Taylor & Francis Ltd.
English
Journal
AB The functions of PACAP and VIP are thought to be exerted through the activation of three types of PACAP/VIP receptors: PAC1, VPAC1 and VPAC2 receptors. In neuronal tissues, these neuropeptides bind specifically to the PACAP-specific (PAC1) receptor and stimulate cAMP accumulation, and PACAP is approx. 103-fold more potent than VIP in these activities mediated through PAC1 receptor. In this study, the authors prepared a series of chimeric peptides in which the N-terminal residues of PACAP27/VIP replaced each other. The authors investigated the effects of these chimeric peptides on the activities of adenylyl cyclase and nitric oxide synthase in neuron-like PC12 cells. N-terminal substitution between PACAP27 and VIP significantly affected the biol. activity, whereas it showed no significant effect on the C-terminal α -helical structure of PACAP27/VIP. These results suggested that the random N-terminal structures in PACAP27/VIP play important roles in their activities and receptor specificity.
CC 2-2 (Mammalian Hormones)
REFERENCE COUNT: 19
THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

L33 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 16
ACCESSION NUMBER: 2002:495925 CAPLUS Full-text
DOCUMENT NUMBER: 137:261273
TITLE: PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126
Onoue, Satomi; Ohshima, Keiichi; Endo, Kouke; Yajima, Takehiko; Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Morioka, Ibaraki, 302-0104, Japan
PES Letters (2002), 522(1-3), 65-70
CODEN: FEBIAL; ISSN: 0014-5793
Elsevier Science B.V.
English
Journal
AB Misfolding of the prion protein yields amyloidogenic isoforms, and it shows exacerbating neuronal damage in neurodegenerative disorders including prion diseases. Pituitary adenylyl cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) potentially stimulate neurogenesis and survival of neuronal cells in the central nervous system. Here, we tested these neuropeptides on neurotoxicity in PC12 cells induced by the prion protein fragment 106-126 [PrP (106-126)]. Concomitant application of neuropeptide with PrP(106-126) (5x10⁻⁵ M) inhibited the delayed death of neuron-like PC12 cells. In particular, PACAP27 inhibited the neurotoxicity of PrP(106-126) at low concns. (>10⁻¹⁵ M), characterized by the deactivation of PrP(106-126)-stimulated caspase-3. The neuroprotective effect of PACAP27 was antagonized by the selective PKA inhibitor, H89, or the MAP kinase inhibitor, U0126. These results suggest that PACAP27 attenuates PrP(106-126)-induced

41

10/536880

delayed neurotoxicity in PC12 cells by activating both PKA and MAP kinases mediated by PAC1 receptor.
CC 14-10 (Mammalian Pathological Biochemistry)
REFERENCE COUNT: 27
THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 17
ACCESSION NUMBER: 2002:561620 CAPLUS Full-text
DOCUMENT NUMBER: 137:346531
TITLE: Pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide attenuate glutamate-induced mNOS activation and cytotoxicity
Onoue, Satomi; Endo, Kouke; Yajima, Takehiko; Kashimoto, Kazuhisa Health Science Division, Itoham Foods Inc., Ibaraki, Morioka, 302-0104, Japan
Regulatory Peptides (2002), 107(1-3), 43-47
CODEN: REPPDY; ISSN: 0167-0115
Elsevier Science Ltd.
English
Journal
AB Both vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) act as neurotransmitters in the central and peripheral nervous systems. Attention has been focused on these neuropeptides because among their numerous biol. activities, they have been confirmed to show neuroprotective effects against ischemia and glutamate-induced cytotoxicity. It is well established that glutamate has excitatory effects on neuronal cells, and that excessive glutamate shows potent neurotoxicity, especially in neuronal nitric oxide synthase-containing neurons. Glutamate stimulates the production of nitric oxide (NO) in neurons, and the NO generated is tightly associated with the delayed death of neurons. We examined the effects of these neuropeptides on the glutamate-induced neuronal actions using PC12 cells, and we confirmed the important activities of PACAP/VIP on the production of NO as well as the delayed cell death stimulated by glutamate.
CC 2-5 (Mammalian Hormones)
REFERENCE COUNT: 37
THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 18
ACCESSION NUMBER: 1986:531504 CAPLUS Full-text
DOCUMENT NUMBER: 105:131504
TITLE: Changes of glycogen and ubiquinone contents in the rat liver during hypovolemia and hepatic arterial ligation
Asaki, Shinichiro; Tanaka, Souichi; Sugishita, Takeo; Endo, Kenzaburo; Yoshida, Satoru; Matsumoto, Akihiko
Dep. Surg., Yokohama Koukan Hosp., Yokohama, 231, Japan
Yokohama Igaku (1986), 37(2), 115-22
CODEN: YKIGAK; ISSN: 0372-7726
Journal
Japanese
AB Changes in glycogen and ubiquinone contents in rat liver were examined after removal of 10 mL/kg of blood and occlusion of the hepatic artery. The mean contents of coenzyme Q10 and coenzyme Q9 at 4 h after blood removal and 3 h after hepatic artery occlusion were 76 and 103% of the control level, resp. Glycogenolysis was increased after blood removal and hepatic artery occlusion.
CC 14-5 (Mammalian Pathological Biochemistry)

42

10/536880

L33 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005.1171442 CAPLUS Full-Text
 DOCUMENT NUMBER: 143:446712
 TITLE: Corneal neurotogenesis promoter containing PACAP and its derivative
 INVENTOR(S): Takayama, Yoshiko; Nakamura, Yoshikuni; Inoue, Yutaka; Yabuta, Chihou; Azuma, Mitsuyoshi; Onoue, Satomi
 PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Itoham Foods Inc.
 SOURCE: PCT Int. Appl., 65 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102375	A1	20051103	WO 2005-JP7609	20050421
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, GU, HD, IE, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2563882	A1	20051103	CA 2005-2563882	20050421
JP 2004-128581 A 20040423				
JP 2004-330464 A 20041115				
WO 2005-JP7609 W 20050421				
MARPAT 143:446712				

PRIORITY APPLN. INFO.:
 CA 2563882 A1 20051103 CA 2005-2563882 20050421
 JP 2004-128581 A 20040423
 JP 2004-330464 A 20041115
 WO 2005-JP7609 W 20050421

OTHER SOURCE(S):
 AB It is intended to provide a corneal neurotogenesis promoter containing PACAP pituitary adenylylate cyclase-activating polypeptide), a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, a corneal neurotogenesis promoter aiming at improving corneal perception, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neurotogenesis. This corneal neurotogenesis promoter is useful as a drug for ameliorating reduction in corneal perception following corneal surgeries such as laser keratotomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal perception accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal perception. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal perception and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal perception accompanying therewith. For example, a peptide PACAP-27 was prepared, and examined for its effect on neurotogenesis in rabbits. Also, an eye drop containing PACAP-27 10 μg was formulated.

IC ICM A61K038-00

ICS A61P027-02

CC 63-6 (Pharmaceuticals)

IT 127317-03-7P 128606-20-2P, PACAP38 129069-75-6P, PACAP27


137061-48-4P, Pituitary adenylylate cyclase-activating polypeptide

10/536880


700368-79-2P 700368-81-6P 700368-83-8P 700368-85-0P
 700368-87-2P 700368-90-7P 700368-92-9P 700368-94-1P
 700368-96-3P 700368-98-5P 700369-00-2P 735327-72-7P
 868367-64-0P 868367-65-1P 868367-70-8P 868367-71-9P
 868367-72-0P 868367-73-1P 868367-91-3P 868367-93-5P
 868367-97-9P 868368-02-9P 868368-03-0P
 868368-04-1P 868368-05-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (corneal neurotogenesis promoter containing PACAP and its derivative)
 IT 700368-83-8P 700368-85-0P 700368-87-2P
 700368-90-7P 700368-96-3P 735327-72-7P
 868367-65-1P 868367-70-8P 868367-91-3P
 868367-97-9P 868368-02-9P 868368-03-0P
 868368-04-1P 868368-05-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (corneal neurotogenesis promoter containing PACAP and its derivative)
 RN 700368-83-8 CAPLUS
 CN Glycinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




Absolute stereochemistry.


PAGE 1-C




PAGE 1-A




PAGE 1-D




PAGE 1-B



PAGE 1-E




PAGE 1-C



RN 700368-85-0 CAPLUS
 CN L-Lysine, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparagyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)


10/536880

PAGE 1-D




10/536880


PAGE 1-B



PAGE 1-E




PAGE 1-C




RN 700368-87-2 CAPLUS
 CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyll-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyll-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-D



10/536880


PAGE 1-E




RN 700368-90-7 CAPLUS
 CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arganyl-L-arganyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isooleucyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




10/536880


PAGE 1-C



PAGE 1-D



PAGE 1-E




RN 700368-96-3 CAPLUS
 CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arganyl-L-arganyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-

10/536880

valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




10/536880


PAGE 1-D



PAGE 1-B



PAGE 1-E








RN 735327-72-7 CAPLUS

CN L-Arginamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 868367-65-1 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-iso-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868367-70-8 CAPLUS
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-iso-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868367-91-3 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-glutamyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-iso-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868367-97-9 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-iso-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868368-02-9 CAPLUS
CN L-Argininamide, N-acetyl-L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-iso-leucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868368-03-0 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-iso-leucyl-

10/536880

L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-
leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-
arganyl-L-valyl-L-arginyl-L-asparagyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868368-04-1 CAPLUS

CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-
L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-
arganyl-L-valyl-L-arginyl-L-asparagyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 868368-05-2 CAPLUS

CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-isoleucyl-
L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-
arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-
valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-
leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:957355 CAPLUS Full-text

DOCUMENT NUMBER: 141:428007

TITLE: Remedies for chronic lung disease containing VIP or

PACAP-derived peptides

INVENTOR(S): Ogami, Masayoshi; Endo, Kosuke; Kashimoto,

Kazuhisa

PATENT ASSIGNEE(S): Ito Ham Foods, Inc., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 60 pp.

CODEN: JKXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004315436	A	20041111	JP 2003-112096	20030416
PRIORITY APPLN. INFO.: JP 2003-112096 20030416				
AB The invention relates to a remedy for chronic lung disease, eg., chronic obstructive pulmonary disease and pulmonary emphysema, characterized by containing vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase activating polypeptide (PACAP)-derived peptides. A peptide His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Tyr-Thr-Arg-Arg-Arg-Gln-Leu-Ala-Val-Arg-Arg-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Gly-Lys-Arg-NH2 was prepared, and examined for its protective effect against tobacco extract-induced apoptosis of cultured L2 cells.				

IC ICM A61K038-22

ICS A61P011-00; C07K014-47; C07K019-00; C12N015-09

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT 40077-57-4P, Vasoactive intestinal octacosapeptide (swine) 60703-95-9P

10/536880

127317-03-7P 176785-24-3P 176785-25-4P 475083-13-7P
700368-79-2P 700368-81-6P 700368-83-8P 700368-85-0P
700368-87-2P 700368-90-7P 700368-98-5P 700369-00-2P
700369-02-4P 735327-71-6P 735327-72-7P 791837-97-3P
791837-98-4P 791908-16-2P 791908-17-3P 791908-18-4P 791908-19-5P
791908-20-8P 791908-21-9P 791908-22-0P 791908-23-1P 791908-24-2P
791908-25-3P 791908-26-4P 791908-27-5P 791908-28-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(remedies for chronic lung disease containing VIP or PACAP-derived peptides)

IT 176785-24-3P 700368-83-8P 700368-85-0P

700368-87-2P 700368-90-7P 735327-72-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(remedies for chronic lung disease containing VIP or PACAP-derived peptides)

RN 176785-24-3 CAPLUS

CN L-Leucinamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-

phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-


arganyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-

valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-


(9CI) (CA INDEX NAME)






Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






700368-83-8 CAPLUS
Glycinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginy-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/536880

PAGE 1-D




10/536880


PAGE 1-B



PAGE 1-E




PAGE 1-C




RN 700368-85-0 CAPLUS
 CN L-Lysinamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-D



10/536880


PAGE 1-E




RN 700368-87-2 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




10/536880


PAGE 1-C



PAGE 1-D








PAGE 1-E



RN 700368-90-7 CAPLUS
CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.







RN 735327-72-7 CAPLUS

CN L-Arginamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L33 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:449513 CAPLUS Full-text
 DOCUMENT NUMBER: 139:240497

TITLE: The structural biology of VIP (2): biological activity of VIP is dependent on its secondary structure

AUTHOR(S): Onoue, Satoshi; Matsumoto, Asami; Nagano, Yumiko; Ohehima, Keiichi; Ohmori, Yuki; Yamada, Shizuo; Kimura, Ryohai; Yajima, Takehiko; Kashimoto, Kazuhisa
 CORPORATE SOURCE: Health Science Division, Itoham Food Inc., Moriya, Ibaraki, 302-0104, Japan
 SOURCE: Peptide Science (2003), Volume Date 2002, 39th, 225-228
 CODEN: PSCIFQ; ISSN: 1344-7661
 PUBLISHER: Japanese Peptide Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The conformational properties of vasoactive intestinal peptide (VIP) include the presence of a randomized structure in the N-terminus and along α -helical structure in the C-terminus. It is still unclear how the formation of the long α -helical structure plays a role in its biol. functions. Here, in order to address this issue, we chemical synthesized VIP analogs modified at the α -helical region and evaluated their structural and biol. activities. The results have shown that the α -helical structure forming in 14 amino acid residues between positions 10 and 23 may be required for the biol. functions of VIP.

CC 2-2 (Mammalian Hormones)
 REFERENCE COUNT: 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:428689 CAPLUS Full-text
 DOCUMENT NUMBER: 136:406898

TITLE: Powder compositions and process for producing the same

INVENTOR(S): Onoue, Satoshi; Endo, Kousuke; Kashimoto, Kazuhisa
 PATENT ASSIGNEE(S): Itoham Foods Inc., Japan
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1

10/536880

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2002043703 A1 20020606 WO 2001-JP10445 20011129
 W: AU, CA, CN, IN, KR, US
 RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR
 JP 2002284703 A 20021003 JP 2001-88337 20010326
 CA 2430318 A1 20020606 CA 2001-2430318 20011129
 AU 200218503 A 20020611 AU 2002-18503 20011129
 JP 2003034652 A 20030207 JP 2001-364325 20011129
 EP 1348428 A1 20031001 EP 2001-98330 20011129
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR
 US 2004109827 A1 20040610 US 2003-432352 20030529
 IN 2003CN01013 A 20050422 IN 2003-CN1013 20030626
 PRIORITY APPL. INFO.: JP 2000-362704 A 20001129
 JP 2001-88337 A 20010326
 JP 2001-364325 A 20011129
 WO 2001-JP10445 W 20011129

AB Disclosed are powdery compns. obtained by mixing fine particles containing a powdery drug and a filler and having an average particle size of $\leq 20 \mu\text{m}$ with a carrier having an aerodynamically acceptable particle size. These preps. can be easily handled in manufacturing and sustain a constant drug content due to the improved dispersibility. A powder composition containing glucagon, erythritol, and lactose was prepared, and evaluated as a dry powder inhalant.

IC ICM A61K009-14

ICS A61K009-127; A61K009-19; A61K009-72; A61K047-10; A61K038-00

CC 63-6 (Pharmaceuticals)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:28756 CAPLUS Full-text
 DOCUMENT NUMBER: 141:76535
 TITLE: Development of a new derivative of vasoactive intestinal peptide and its novel administration system, dry powder inhalation
 AUTHOR(S): Endo, Kosuke; Onoue, Satomi; Amikawa, Satoko; Matsumoto, Asami; Waki, Yoshihiro; Yamana, Masaya; Kondo, Masaaki; Hamanaka, Kazuya; Suitani, Yoshihiko; Kashimoto, Kazuhisa
 CORPORATE SOURCE: Health Science Div., Itoham Food Inc., Moriya, Ibaraki, 302-0104, Japan
 SOURCE: Peptides 2002, Proceedings of the European Peptide Symposium, 27th, Sorrento, Italy, Aug. 31-Sept. 6, 2002 (2002), 944-945. Editor(s): Benedetti, Ettore; Pedone, Carlo. Edizioni Ziino: Castellammare di Stabia, Italy.
 CODEN: 69EYXG; ISBN: 88-900948-1-8
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB The synthesis of a new vasoactive intestinal peptide (VIP) named IK12532, which was modified to increase its stability against enzymic digestion is discussed. The formulation of a topical administration system, dry powder inhalation (DPI) is reported. Results showed that both IK12532 and VIP showed potent relaxation of isolated tracheal smooth muscle in a dose-dependent manner. IK12532 was approx. 103-fold more potent in inducing relaxation than theophylline after histamine (10-5 M)-induced contraction and

67

10/536880

had an EC50 value of 2.0×10^{-7} M. The addition of peptidase, including trypsin, to a solution of IK12532 or VIP showed the time-dependent digestion of these peptides, and also revealed that the elimination of IK12532 was much slower than that of VIP. These results suggest that the duration of IK12532 was due to its stability against peptidase-induced elimination. On the other hand, when IK12532 was applied to the optimized DPI formula, erythritol-excipient/erythritol-carrier, the RF value was estimated to be up to 19.7%. However, erythritol-excipient/Pharmatose-carrier blend had a better RF value of 29.2%, indicating that the optimized formula of DPI was dependent on each pharmaceutical agent. Considered with other peptides, this formula, with the use of erythritol for the excipient and/or carrier, is applicable to the peptide/protein.

CC 63-6 (Pharmaceuticals)

REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:517561 CAPLUS Full-text

DOCUMENT NUMBER: 137:363243

TITLE: The relaxation effects of VIP and its C-terminal

deleted peptides on mouse stomach

AUTHOR(S): Nagano, Yumiko; Matsumoto, Asami; Onoue, Satomi; Harada, Sunao; Mizumoto, Kazuhisa

Kashimoto, Kazuhisa

Health Science Division, ITOHAM FOODS INC., Moriya,

Ibaraki, 302-0104, Japan

SOURCE: Peptide Science (2002), Volume Date 2001, 38th, 147-150

CODEN: PSCIFQ; ISSN: 1344-7661

DOCUMENT TYPE: Japanese Peptide Society

LANGUAGE: English

AB Some brain-gut/gastrointestinal peptides, belonging to glucagon-secretin family, are well-known to have the potent inhibitory effects on gastric motility. In this study, we investigated the relaxation effects of some peptides of this family on mouse stomach using some family peptides, and we confirmed the most potent activity of VIP among tested peptides. We, therefore, have been interested in this relaxation activity and structure of VIP, so we clarified the relationship between its structures and activities of shortened VIP-derivs., which were truncated at N- or C-terminal ends. These investigations gave us further information concerning with a min. peptide fragment of VIP, which was necessary for a potent relaxation effect on mouse stomach.

CC 2-2 (Mammalian Hormones)

DOCUMENT TYPE: 11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:550347 CAPLUS Full-text

DOCUMENT NUMBER: 129:224450

TITLE: Insulating film, semiconductor device using such film,

and method for manufacture thereof

INVENTOR(S): Matsubara, Takahisa; Noguchi, Nobu; Ito, Shinya; Ota,

Noriaki; Matsumoto, Akira; Ishigami,

Takashi; Nakamae, Masahiko; Horuchi, Tadahiko;

Endo, Kazuhiko; Tatsumi, Toru; Matsumoto,

Yoshihige

PATENT ASSIGNEE(S): NEC Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.

68

10/536880

10/536880

CODEN: JKXAF

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10223625	A	19980821	JP 1997-148017	19970605
JP 3228183	B2	20011112		
US 6091081	A	20000718	US 1997-982585	19971202
GB 2334818	B	20000719	GB 1999-11186	19971202
US 6372628	B1	20020416	JP 1996-321694	20000526
			JP 1997-148017	A 19970605
			GB 1997-25525	A3 19971202
			US 1997-982585	A3 19971202

PRIORITY APPLN. INFO.:

AB An insulating film is obtained by coating H-containing diamond-like C onto 1 surface of amorphous C fluoride film and then coating a Si(O,N), Si3N4, or SiO2 films containing excess Si. Via holes are formed by anisotropic etching with O plasma of the diamond-like C film and amorphous C fluoride film.

IC ICM H01L021-314

CC ICS H01L021-3065; H01L021-768; H01L021-205

CC 76-3 (Electric Phenomena)

L33 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989-554419 CAPLUS Full-text

DOCUMENT NUMBER: 111:154419

TITLE: Radical polymerization of vinyl esters with a bulky

AUTHOR(S): Otsu, Takayuki; Matsumoto, Akikazu;

Endo, Kiyoshi; Kataoka, Hiroyuki

Dep. Appl. Chem., Osaka City Univ., Osaka, Japan

Members of the Faculty of Engineering, Osaka City

University (1988), 29, 161-9

CODEN: MFEQAR; ISSN: 0078-6659

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The radical polymerization reactivities of vinyl pivalate (I), vinyl benzoate (II), and vinyl p-tert-butylbenzoate (III) were investigated and compared with that of vinyl acetate (IV). The polymerization rates in bulk were in the following order: IV > I > III > II. The polymerization reactivities were lower than those of the aliphatic carboxylates, and the introduction of a bulky tert-Bu group into II increased the polymerization activity. The overall activation energy of the polymerization of I in benzene was 109 kJ/mol. These polymers, except for IV, were thermally stable (Tmax = 330-350°). The tacticity of the polymers was determined by 13C NMR after their conversion to poly(vinyl acetate) by hydrolysis and acetylation.

CC 35-3 (Chemistry of Synthetic High Polymers)

L33 ANSWER 26 OF 32 MEDLINE on STN

ACCESSION NUMBER: 199953196 MEDLINE Full-text

DOCUMENT NUMBER: Pubmed ID: 10119638

TITLE: Invasive thymoma associated with pure red cell aplasia and liver metastasis: a case report.

AUTHOR: Iishiwa N; Yamamoto Y; Tanaka S; Yamada R; Wada N; Kumakiri

Y; Takahashi M; Kasahara A; Endo K; Yoshida S;

CORPORATE SOURCE:

SOURCE:

PUB. COUNTRY:

DOCUMENT TYPE:

LANGUAGE:

FILE SEGMENT:

ENTRY MONTH:

ENTRY DATE:

Last Updated on STN: 18 Jun 1999

Entered Medline: 4 Jun 1999

ABSTRACT:

A case of invasive thymoma associated with pure red cell aplasia and liver

metastasis was reported. A 57-year-old male was admitted to our hospital

because of hepatic abnormal shadow on computed tomography. Malignant tumor was

suspected by imaging procedures. Left lateral segmental resection of liver was

performed and histo-pathological examination proved the tumor to be liver

metastasis of thymoma. He was received 50 Gy irradiation after incomplete

resection of thymoma. In the course of time he contracted pure red cell

aplasia. But he is well controlled medically and alive 7 years after the

surgery.

CONTROLLED TERM:

Check Tags: Male

English Abstract

Humans

Liver Neoplasms: RA, radiography

*Liver Neoplasms: SC, secondary

Middle Aged

*Red-Cell Aplasia, Pure: ET, etiology

Thymoma: CO, complications

*Thymoma: PA, pathology

Thymoma: RA, radiography

*Thymoma: SC, secondary

Thymus Neoplasms: CO, complications

*Thymus Neoplasms: PA, pathology

Tomography, X-Ray Computed

L33 ANSWER 27 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on

STN

ACCESSION NUMBER: 2003:433741 BIOSIS Full-text

DOCUMENT NUMBER: PREV200300433741

TITLE: Vasoactive intestinal peptide protects rat alveolar L2 cell

from the cytotoxicity of cigarette smoke.

Onoue, Satoshi [Reprint Author]; Endo,

Kosuke [Reprint Author]; Ohmori, Yuki; Yamada, Shizuo;

Kimura, Ryohei; Yajima, Takehiko; Kashimoto, Kazuhisa

[Reprint Author]

CORPORATE SOURCE: Health Sci. Div., Itoham Foods Inc., Ibaraki, 302-0104,

Japan

SOURCE: Regulatory Peptides, (15 August 2003) Vol. 115, No. 1, pp.

53. Print.

Meeting Info: 6th International Symposium on VIP, PACAP

and Related Peptides. Hakone, Japan. September 01-04, 2003.

ISSN: 0167-0115 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)

LANGUAGE: English

ENTRY DATE: Entered STN: 17 Sep 2003

10/536880

CONCEPT CODE: Last Updated on STN: 17 Sep 2003
General biology - Symposia, transactions and proceedings 00520
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Respiratory system - Physiology and biochemistry 16004
Respiratory system - Pathology 16006
Toxicology - General and methods 22501
Major Concepts
INDEX TERMS: Respiratory System (Respiration); Toxicology Diseases
INDEX TERMS: chronic obstructive pulmonary disease: respiratory system disease, COPD
INDEX TERMS: Lung Diseases, Obstructive (MeSH)
Chemicals & Biochemicals
DNA: fragmentation; LDH [lactate dehydrogenase]; caspase-3; matrix metalloproteinase [MMP]; vasoactive intestinal peptide [VIP]
INDEX TERMS: Miscellaneous Descriptors
cigarette smoke: cytotoxicity
ORGANISM: Classifier
Muriidae 86175
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
L2 cell line (cell line): rat alveolar cells
rat (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
9001-60-9 (LDH)
9001-60-9 (lactate dehydrogenase)
169592-56-7 (caspase-3)
141907-41-7 (matrix metalloproteinase)
141907-41-7 (MMP)
37221-79-7 (vasoactive intestinal peptide)
37221-79-7 (VIP)

L33 ANSWER 28 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on

STN
ACCESSION NUMBER: 2007:21901 BIOSIS Full-text
DOCUMENT NUMBER: PREV200700034563
TITLE: Alpha-helical structure of vasoactive intestinal peptide is essential to its biological functions.
AUTHOR(S): Onoue, Satoshi [Reprint Author]; Matsumoto, Asumi; Ohmori, Yuki; Yamada, Shizuo; Liu, Baosheng; Yajima, Takehiko
CORPORATE SOURCE: Ito Life Sci Inc, Ibaraki 3020104, Japan
SOURCE: Flegel, M [Editor]; Fridkin, M [Editor]; Gilon, C [Editor]; Slaninova, J [Editor]. (2005) pp. 742-743. Peptides 2004, Proceedings: BRIDGES BETWEEN DISCIPLINES.
PUBLISHER: KENES INTERNATIONAL, 17 RUE DU CENDRIER, PO BOX 1726, GENEVA 1, CH-1211, SWITZERLAND.
Meeting Info: 3rd International Peptide Symposium/28th European Peptide Symposium. Prague, CZECH REPUBLIC. September 05 -10, 2004.

10/536880

ISBN: 965-90833-0-0 (H)
Book; (Book Chapter)
Conference; (Meeting)
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Dec 2006
Last Updated on STN: 27 Dec 2006
CONCEPT CODE: Behavioral biology - Human behavior 07004
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Pathology - Therapy 12512
Metabolism - Metabolic disorders 13020
Respiratory system - Pathology 16006
Reproductive system - Pathology 16506
Endocrine - Pancreas 17008
Nervous system - Pathology 20506
Psychiatry - Psychopathology, psychodynamics and therapy 21002
Pharmacology - General 22002
Pharmacology - Drug metabolism and metabolic stimulants 22003
Pharmacology - Clinical pharmacology 22005
Immunology - Immunopathology, tissue immunology 34508
Allergy 35500
Major Concepts
Pharmacology
Diseases
asthma: respiratory system disease, immune system disease, drug therapy
Asthma (MeSH)
Diseases
diabetes: endocrine disease/pancreas, metabolic disease, drug therapy
Diabetes Mellitus (MeSH)
Diseases
dementia: nervous system disease, behavioral and mental disorders, drug therapy
Dementia (MeSH)
Diseases
impotence: reproductive system disease/male, behavioral and mental disorders, drug therapy
Impotence (MeSH)
Diseases
inflammation: immune system disease, drug therapy
Inflammation (MeSH)
INDEX TERMS: Chemicals & Biochemicals
nitric oxide synthase [EC 1.14.13.39]; adenylate cyclase [EC 4.6.1.11]; PACAP; neurite outgrowth factor; vasoactive intestinal peptide [VIP]; metabolic-drug
CLASSIFIER
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common)
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
125978-95-2 (nitric oxide synthase)

10/536880

125978-95-2 (EC 1.14.13.39)
9012-42-4 (adenylate cyclase)
9012-42-4 (EC 4.6.1.1)
137061-48-4 (PACAP)
37221-79-7 (vasoactive intestinal peptide)
37221-79-7 (VIP)

L33 ANSWER 29 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
ACCESSION NUMBER: 2003:213128 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300213128
TITLE: Structure-activity relationship of vasoactive intestinal peptide (VIP) analogues.
AUTHOR(S): Omori, Yuki; Yamada, Shizuo [Reprint Author]; Kimura, Ryohei [Reprint Author]; Onoue, Satoshi; Matsumoto, Asami; Endo, Kosuke; Kashimoto, Kazuhisa
CORPORATE SOURCE: Dept. Biopharm., Sch. Pharm. Sci., Univ. Shizuoka, Shizuoka, 422-8526, Japan
SOURCE: Journal of Pharmacological Sciences, (2003) Vol. 91, No. Supplement 1, pp. 237p. print.
Meeting Info.: 76th Annual Meeting of the Japanese Pharmacological Society, Fukuoka, Japan. March 24-26, 2003. Japanese Pharmacological Society.
ISSN: 1347-8613 (ISSN print).

DOCUMENT TYPE: Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 30 Apr 2003
Last Updated on STN: 30 Apr 2003
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520

Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Digestive system - Physiology and biochemistry 14004
Respiratory system - Physiology and biochemistry 16004
Muscle - Physiology and biochemistry 17504
Major Concepts

Biochemistry and Molecular Biophysics
Parts, Structures, & Systems of Organisms
lung; respiratory system; smooth muscle; muscular system; relaxation; stomach; digestive system
Chemicals & Biochemicals
asparagine; asparaginic acid; carbachol; hormone; secretion; methionine; neuropeptide; amino acid sequences; threonine; vasoactive intestinal peptide [VIP]; analogues, structure-activity relationships; vasoactive intestinal peptide receptor [VIP receptor]
Miscellaneous Descriptors
vasodilation

ORGANISM: Classifier
Muriidae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates

73

10/536880

REGISTRY NUMBER: 70-47-30 (asparagine)
3130-87-8Q (asparagine)
56-84-8 (asparaginic acid)
51-83-2 (carbachol)
59-51-8Q (methionine)
63-68-3Q (methionine)
72-19-5Q (threonine)
80-68-2Q (threonine)
37221-79-7 (vasoactive intestinal peptide)
37221-79-7 (VIP)

L33 ANSWER 30 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
ACCESSION NUMBER: 2003:433739 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300433739
TITLE: Pharmacological usefulness of dry powder inhaler of a novel vasoactive intestinal peptide (VIP) analogue as anti-asthma agent.

AUTHOR(S): Omori, Y. [Reprint Author]; Yamada, S. [Reprint Author]; Kimura, R. [Reprint Author]; Onoue, S.; Matsumoto, A.; Endo, K.; Iwanaga, T.; Kashimoto, K.

CORPORATE SOURCE: Sch. Pharm. Sci. and COE21, Univ. of Shizuoka, Shizuoka, Japan

SOURCE: Regulatory Peptides, (15 August 2003) Vol. 115, No. 1, pp. 52. print.
Meeting Info.: 6th International Symposium on VIP, PACAP and Related Peptides. Hakone, Japan. September 01-04, 2003. ISSN: 0167-0115 (ISSN print).

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 17 Sep 2003

Last Updated on STN: 17 Sep 2003

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520

Cytology - Animal 02506

Cytology - Human 02508

Biochemistry studies - Proteins, peptides and amino acids 10064

Pathology - Therapy 12512

Blood - Blood and lymph studies 15002

Blood - Blood cell studies 15004

Respiratory system - Physiology and biochemistry 16004

Respiratory system - Pathology 16006

Pharmacology - General 22002

Pharmacology - Clinical pharmacology 22005

Pharmacology - Respiratory system 22030

Immunology - General and methods 34502

Immunology - Immunopathology, tissue immunology 34508

Allergy 35500

Major Concepts

INDEX TERMS: Pharmacology; Pulmonary Medicine (Human Medicine, Medical Sciences)

INDEX TERMS: Parts, Structures, & Systems of Organisms
eosinophil; blood and lymphatics, immune system; granulocyte; blood and lymphatics, immune system; lung; respiratory system; neutrophil; blood and lymphatics, immune system; trachea; respiratory system
Diseases

74

10/536880

asthma: immune system disease, respiratory system disease
Asthma (MeSH)
Diseases
pulmonary disease: respiratory system disease
Lung Diseases (MeSH)
Chemicals & Biochemicals
IX312532: antiasthmatic-drug, inhalation administration, powder; vasoactive intestinal peptide [VIP]: antiasthmatic-drug, analogue, inhalation administration
Methods & Equipment
drug powder inhaler: drug delivery device
Classifier
Caviidae 86300
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
guinea-pig (common): animal model
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common): patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
37221-79-7 (vasoactive intestinal peptide)
37221-79-7 (VIP)

REGISTRY NUMBER:

L33 ANSWER 31 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER:

PREV200200557424

DOCUMENT NUMBER:

Development of a new derivative of vasoactive intestinal peptide and its novel administration system, dry powder inhalation.

AUTHOR(S):

Endo, K. [Reprint author]; Onoue, S. [Reprint author]; Amikawa, S. [Reprint author]; Matsumoto, A. [Reprint author]; Waki, Y. [Reprint author]; Yamanaka, M. [Reprint author]; Kondo, M. [Reprint author]; Hatanaka, K. [Reprint author]; Suitani, Y. [Reprint author]; Kashimoto, K. [Reprint author]; Health Science Div., Itoham Food Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki, 302-0104, Japan
Journal of Peptide Science, (2002) Vol. 8, No. Supplement, pp. S214. print.
Meeting Info.: 27th European Peptide Symposium. Sorrento, Italy, August 31-September 06, 2002.
ISSN: 1075-2617
Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
English
Entered STN: 30 Oct 2002
Last Updated on STN: 30 Oct 2002
General biology - Symposia, transactions and proceedings

CORPORATE SOURCE:

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

ENTRY DATE:

CONCEPT CODE:

10/536880

00520
Biochemistry studies - Proteins, peptides and amino acids
10064
Pathology - Therapy 12512
Respiratory system - Pathology 16006
Pharmacology - General 22002
Pharmacology - Respiratory system 22030
Immunology - Immunopathology, tissue immunology 34508
Allergy 35500
Major Concepts
Pharmaceuticals (Pharmacology)
Diseases
asthma: immune system disease, respiratory system disease
Asthma (MeSH)
Chemicals & Biochemicals
vasoactive intestinal peptide: vasoactive intestinal peptide derivative: bronchodilator-drug, nasal administration; vasoactive intestinal peptide receptor
Methods & Equipment
Jet Haler: drug delivery device
Miscellaneous Descriptors
Meeting Abstract; Meeting Poster
37221-79-7 (vasoactive intestinal peptide)
37221-79-7D (vasoactive intestinal peptide)

REGISTRY NUMBER:

L33 ANSWER 32 OF 32 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER:

PREV200200557266

DOCUMENT NUMBER:

Pituitary adenylate cyclase activating polypeptide inhibited the beta-amyloid-induced neurotoxicity and activation of caspase-3.

AUTHOR(S):

Endo, K. [Reprint author]; Ohshima, K.; Yajima, T.; Kashimoto, K. [Reprint author]
Itoham Foods Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki, 302-0104, Japan
Journal of Peptide Science, (2002) Vol. 8, No. Supplement, pp. S170. print.
Meeting Info.: 27th European Peptide Symposium. Sorrento, Italy, August 31-September 06, 2002.
ISSN: 1075-2617
Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
English
Entered STN: 30 Oct 2002
Last Updated on STN: 30 Oct 2002
General biology - Symposia, transactions and proceedings

CORPORATE SOURCE:

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

ENTRY DATE:

CONCEPT CODE:

00520
Cytology - Animal 02506
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Nervous system - Physiology and biochemistry 20504
Nervous system - Pathology 20506
Major Concepts

INDEX TERMS:

10/536880

Biochemistry and Molecular Biophysics; Nervous System
(Neural Coordination)

INDEX TERMS: Parts, Structures, & Systems of Organisms

INDEX TERMS: neuron; nervous system

Diseases Alzheimer's disease; behavioral and mental disorders,
nervous system disease

Alzheimer Disease (MeSH)

INDEX TERMS: Chemicals & Biochemicals

PAC1 receptor; beta-amyloid; neurotoxicity; caspase-3;
humanin; pituitary adenylate cyclase activating

polypeptide; vasoactive intestinal peptide

INDEX TERMS: Miscellaneous Descriptors

signaling pathway; Meeting Abstract; Meeting Poster

ORGANISM: Classifier

Muridae

Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

PC12 cell line

Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates,

Nonhuman Mammals, Rodents, Vertebrates

169592-56-7 (caspase-3)

137061-48-4 (pituitary adenylate cyclase activating

polypeptide)

37221-79-7 (vasoactive intestinal peptide)

10/536880

=> file registry
FILE 'REGISTRY' ENTERED AT 12:24:03 ON 30 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and

predicted properties as well as tags indicating availability of

experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 12:24:08 ON 30 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6

FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBJ' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L9

L3 113096 SEA FILE-REGISTRY ABB=ON PLU=ON AMI7/NTE

L6 54 SEA FILE-REGISTRY ABB=ON PLU=ON HSDA[IV]FT[DEA] [SND]Y[ST]R[YL]

L8 1RROLAVRYLAA/SOSP

L9 30 SEA FILE-REGISTRY ABB=ON PLU=ON L6 AND L3


L8 4 SEA FILE-CAPLUS ABB=ON PLU=ON L8

10/536880

-> d stat que L16
L10 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading L10.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46 47 48
49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
70 71 72
73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 97 98 99
100 101 104

ring nodes :
91 92 93 94 95 96
chain bonds :
1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69
17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 31-98 32-51
33-34 33-99
34-52 35-36 35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-
58 58-61
59-61 60-61 62-63 63-64 64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73
77-78 78-79 79-80
80-81 81-82 81-83 84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97
ring bonds :
91-95 91-92 92-93 93-94 94-96 95-96
exact/norm bonds :
1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69

10/536880

17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 32-51 33-34
34-52 35-36
36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-58 58-61 59-61 60-61
62-63 63-64
64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73 77-78 78-79 79-80 80-81
81-82 81-83
84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97
exact bonds :
31-98 33-99 35-100
normalized bonds :
91-95 91-92 92-93 93-94 94-96 95-96

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS
40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS
48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS
58:CLASS 59:CLASS
60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:CLASS 66:CLASS 67:CLASS
68:CLASS 69:CLASS
70:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:CLASS 77:CLASS
78:CLASS 79:CLASS
80:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS 87:CLASS
88:CLASS 89:CLASS
90:CLASS 91:Atom 92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS
99:CLASS
100:CLASS 101:CLASS 104:CLASS

L15 11 SEA FILE=REGISTRY SSS FUL L10
L16 9 SEA FILE=CAPLUS ABB=ON PLU=ON L15

=> s (L9 or L16) not L32
L34 6 (L9 OR L16) NOT L32

=> file toxcenter
FILE 'TOXCENTER' ENTERED AT 12:24:42 ON 30 JAN 2007
COPYRIGHT (C) 2007 ACS

FILE COVERS 1907 TO 30 Jan 2007 (20070130/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2007 MeSH terms and See HELP RLOAD for details.

10/536880


TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MESH 2007 vocabulary.

=> d stat que L28
L6 54 SEA FILE-REGISTRY ABB-ON PLU-ON HSDA(IV) FT(DEA) [SND]Y(ST)R(VL
]RRQLAVRYLAA/SQSP
L10 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:

Uploading L10.str



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46 47 48
49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69
70 71 72
73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 97 98 99
100 101 104

ring nodes :

91 92 93 94 95 96

chain bonds :

1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69
17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 31-98 32-51
33-34 33-99
34-52 35-36
35-100 36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-
58 58-61
59-61 60-61 62-63 63-64 64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73
77-78 78-79 79-80
80-81 81-82 81-83 84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97
ring bonds :
91-95 91-92 92-93 93-94 94-96 95-96
exact/norm bonds :

10/536880

1-12 2-13 2-14 3-15 3-16 4-17 4-18 5-19 5-20 6-21 6-23 7-26 7-27 8-28
8-29 9-30 9-31 10-32 10-33 11-34 11-35 12-13 12-55 13-42 14-15 14-62
15-43 16-17 16-69
17-44 18-19 18-74 19-45 20-21 20-75 21-46 22-38 22-101 23-24 23-76 24-37
24-47 25-37
25-26 25-77 26-48 27-28 27-84 28-49 29-30 29-104 30-50 31-32 32-51 33-34
34-52 35-36
36-53 36-101 38-39 38-54 39-40 39-41 55-56 56-57 57-58 58-61 59-61 60-61
62-63 63-64
64-65 65-68 66-68 67-68 69-70 70-71 71-72 71-73 77-78 78-79 79-80 80-81
81-82 81-83
84-85 85-86 86-87 87-88 88-89 88-90 91-104 94-97
exact bonds :
31-98 33-99 35-100
normalized bonds :
91-95 91-92 92-93 93-94 94-96 95-96

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS
40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS
48:CLASS 49:CLASS
50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS
58:CLASS 59:CLASS
60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:CLASS 66:CLASS 67:CLASS
68:CLASS 69:CLASS
70:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:CLASS 77:CLASS
78:CLASS 79:CLASS
80:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS 87:CLASS
88:CLASS 89:CLASS
90:CLASS 91:Atom 92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:CLASS 98:CLASS
99:CLASS
100:CLASS 101:CLASS 104:CLASS

L15 11 SEA FILE-REGISTRY SSS FUL L10
L26 62 SEA FILE-REGISTRY ABB-ON PLU-ON L6 OR L15
L28 1 SEA FILE-TOXCENTER ABB-ON PLU-ON L26

=> s L28 not L29

L35 0 L28 NOT L29

=> d ibib abs hitind hitstr L34 1-6
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:Y

L34 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:651355 CAPLUS Full-text
DOCUMENT NUMBER: 141:185093
TITLE: PACAP and VIP peptide derivatives as antiinflammatory

10/536880

10/536880

INVENTOR(S): agents
 Yamada, Shizuo; Ogami, Masayoshi; Kashimoto, Kazuhisa
 PATENT ASSIGNEE(S): Ito Ham Foods, Inc., Japan
 Jpn. Kokai Tokkyo Koho, 62 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2004224775 A 20040812 JP 2003-17909 20030127
 JP 2003-17909 20030127
 PRIORITY APPLN. INFO.:
 AB PACAP and VIP peptide derivs. (I) and their pharmaceutically acceptable salts
 in nasal drops, eyedrops, injections, and other topical preps. are claimed as
 antiinflammatory agents for treatment of allergic asthma, bronchitis,
 conjunctivitis, autoimmune disease, atopic dermatitis etc. I were prepared,
 their formulation examples were given, and their VIP receptor-binding affinity
 and antiinflammatory action were tested.

IC ICM A61K038-00
 ICS A61P029-00
 CC 1-7 (Pharmacology)
 Section cross-reference (s): 34, 63
 IT 40077-57-4P, Vasoactive intestinal octacosapeptide (swine) 127317-03-7P
 132333-38-1P 134582-06-2P 134582-07-3P 134582-08-4P 134582-09-5P
 134582-10-8P 176785-24-3P 176785-25-4P 475083-13-7P
 700368-79-2P 700368-81-6P 700368-83-8P 700368-85-0P
 700368-87-2P 700368-90-7P 700368-92-9P 700368-94-1P
 700368-96-3P 700368-98-5P 700369-00-2P 700369-02-4P
 735327-71-6P 735327-72-7P 735327-76-1P 735801-22-6P
 735801-23-7P 735801-24-8P 735801-25-9P 735801-26-0P
 735801-27-1P 735801-28-2P 735801-29-3P 735801-30-6P
 735801-31-7P 735801-32-8P 735801-33-9P
 735801-34-0P 735801-35-1P 735801-36-2P 735801-37-3P
 736969-39-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PACAP and VIP peptide derivs. as antiinflammatory and antiallergic agents)

IT 176785-24-3P 700368-83-8P 700368-85-0P
 700368-87-2P 700368-90-7P 700368-96-3P
 735327-72-7P 735801-24-6P 735801-25-9P
 735801-28-2P 735801-31-7P 735801-32-8P
 735801-33-9P 735801-35-1P 735801-36-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PACAP and VIP peptide derivs. as antiinflammatory and antiallergic agents)


RN 176785-24-3 CAPLUS
 CN L-Leucinamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


83

84


PAGE 1-A



PAGE 1-B




PAGE 1-C




10/536880

PAGE 1-D



10/536880


PAGE 1-B



PAGE 1-E




PAGE 1-C




RN 700368-83-8 CAPLUS
CN Glycinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-D



10/536880


PAGE 1-E




RN 700368-85-0 CAPLUS
 CN L-Lysinamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-threonyl-L-threonyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




10/536880


PAGE 1-C



PAGE 1-D



PAGE 1-E




RN 700368-87-2 CAPLUS
 CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-threonyl-L-threonyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/536880

PAGE 1-A




10/536880


PAGE 1-D



PAGE 1-B



PAGE 1-E






RN 700368-90-7 CAPLUS

CN L-Argininamide, L-histidyl-L-seryl-L- α -aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 700368-96-3 CAPLUS


CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/536880


PAGE 1-C




10/536880

Absolute stereochemistry.


PAGE 1-A




PAGE 1-D




PAGE 1-B



PAGE 1-E





PAGE 1-C



RN 735327-72-7 CAPLUS
 CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-alanyl-L-asparaginyll-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyll-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

93

94



```

RN      735801-24-8  CAPLUS
CN      L-Arginanimide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-L-
        phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-asparaginyL-L-tyrosyl-L-
        threonyl-L-arginyL-L-leucyl-L-arginyL-L-arginyL-L-glutaminyL-L-leucyl-L-
        alanyl-L-valyl-L-arginyL-L-arginyL-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-
        isoleucyl-L-leucylglycyl-L-arginyL- (9CI)  (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN      735801-25-9  CAPLUS
CN      L-Arginanimide, N-acetyl-L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-
        valyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-asparaginyL-L-tyrosyl-
        L-threonyl-L-arginyL-L-leucyl-L-arginyL-L-arginyL-L-glutaminyL-L-leucyl-L-
        alanyl-L-valyl-L-arginyL-L-arginyL-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-
        isoleucyl-L-leucylglycyl-L-arginyL- (9CI)  (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN      735801-28-2  CAPLUS
CN      L-Arginanimide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-valyl-L-
        phenylalanyl-L-threonyl-L- $\alpha$ -glutamyl-L-asparaginyL-L-tyrosyl-L-
        threonyl-L-arginyL-L-leucyl-L-arginyL-L-arginyL-L-glutaminyL-L-leucyl-L-
        alanyl-L-valyl-L-arginyL-L-arginyL-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-
        isoleucyl-L-leucylglycyl-L-arginyL- (9CI)  (CA INDEX NAME)

```

```

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-31-7 CAPLUS
CN   L-Arigininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-32-8 CAPLUS
CN   L-Arigininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-33-9 CAPLUS
CN   L-Arigininamide, N-acetyl-L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-35-1 CAPLUS
CN   L-Arigininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminy-L-arginyl-L-valyl-L-arginyl-L-asparaginyL- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-36-2 CAPLUS
CN   L-Arigininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminy-L-arginyl-L-valyl-L-arginyl-L-asparaginyL- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RR   735801-36-2 CAPLUS
CN   L-Arigininamide, L-histidyl-L-seryl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- $\alpha$ -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutaminy-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-isoleucyl-L-leucylglycyl-L-arginyl-L-arginyl-L-tyrosyl-L-arginyl-L-glutaminy-L-arginyl-L-valyl-L-arginyl-L-asparaginyL- (9CI) (CA INDEX NAME)

L34 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2004:492616 CAPLUS Full-text
DOCUMENT NUMBER: 141:47353
TITLE.: Pharmaceuticals containing peptides for treatment of retinal diseases
INVENTOR(S): Sakamoto, Yuij; Inoue, Atsushi; Yoshida, Masao; Ogami, Masayoshi; Kashimoto, Kazuhisa
PATENT ASSIGNEE(S): Senju Pharmaceutical Co., Ltd., Japan; Ito Ham Foods, Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JFXXAF
PATENT: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

```

10/536880

10/536880

PATENT INFORMATION:

PATENT NO. _____ KIND DATE APPLICATION NO. DATE
 JP 2004168697 A 20040617 JP 2002-335445 20021119
 PRIORITY APPLN. INFO.: JP 2002-335445 20021119
 OTHER SOURCE(S): MARPAT 141:47353
 AB Title pharmaceuticals, which are administered by intravitreal injection, eye drops, etc., contain His-Ser-Asp-Gly-Ile-Phe-Thr-Arg-Ser-Tyr-Ser-Arg-Tyr-Arg-Arg-Gln-X1-Ala-Val-Arg-Tyr-Leu-Ala-Val-Leu-X2-R (I) (X1 = Leu, Met, Nle; X2 = Gly, Gly-Arg, Gly-Lys, Gly-Lys-Arg, Gly-Arg-Arg, bond; R = NH₂, OH; when X2 = bond, then X1 = Met, Nle; when X2 ≠ bond, then X1 = Leu) or their pharmacol. acceptable salts. Thus, intravitreal injection of I (X1 = Leu, X2 = Gly-Arg-Arg, R = NH₂) (at 10 μM in vitreous humor) significantly improved retinal ischemia-reperfusion injury in rats.

IC ICM A61K038-00
 ICS A61P027-02; C07K014-47

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT 705926-31-4 705926-32-5 705926-33-6 705926-34-7

705926-35-8 705926-36-9 705926-37-0 705926-38-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

IT (peptides for treatment of retinal diseases by topical administration)

705926-33-6 705926-34-7 705926-35-8

705926-36-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(peptides for treatment of retinal diseases by topical administration)

RN 705926-33-6 CAPLUS

CN Glycinamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-

prolyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-


tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-

arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl-L-leucyl-


(9Ci) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B




PAGE 1-C




PAGE 1-D








PAGE 1-A









RN 705926-34-7 CAPLUS
 CN L-Lysineamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-prolyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 705926-35-8 CAPLUS
 CN L-Arginineamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-prolyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.







RN 705926-36-9 CAPLUS

L-Arginamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-prolyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-alanyl-L-alanyl-L-valyl-L-leucylglycyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L34 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:240334 CAPLUS Full-text
 DOCUMENT NUMBER: 129:761

TITLE: Sustained relaxant action of [Arg15,20,21, Leu17]-PACAP-27-NH₂ on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro
 AUTHOR(S): Yamada, Yumi; Yoshihara, Shigemi; Kashimoto, Kazuhisa; Linden, Anders; Ichimura, Tohju
 CORPORATE SOURCE: First Department Pediatrics, Dokkyo University School of Medicine, Tochigi, 321-0293, Japan
 SOURCE: Biomedical Research (1998), 19(1), 39-44
 CODEN: BRESDS; ISSN: 0388-6107

PUBLISHER: Biomedical Research Foundation
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Duration of relaxant action of an analog of pituitary adenylate cyclase activating peptide (PACAP)-27, [Arg15,20,21, Leu17]-PACAP-27-NH₂, was compared with that of PACAP-27 in the smooth muscle isolated from guinea-pig trachea. The relaxant action was examined on the prolonged contracted state of the smooth muscle, which had been stimulated with carbachol (CCh; 0.1 μM). Addition of the analog caused concentration-dependent relaxation; both the onset and offset of which were much slower than those with PACAP-27, vasoactive intestinal polypeptide (VIP), and peptide histidine isoleucine (PHI). More than 90% of the maximum relaxation was maintained for 6 h after addition of the analog, whereas the relaxation induced by PACAP-27, VIP, and PHI reached a maximum by 20 min after the addition and was followed by gradual contraction. Influence of peptidases involved in the smooth muscle preparation on the peptides was examined using 10 μM captopril and 1 μM phosphoramidon as peptidase inhibitors. Although the efficacy and duration of the relaxant action with PACAP-27 were significantly potentiated in the presence of peptidase inhibitors, those with the analog were only slightly affected. A conclusion is drawn that the analog has sustained relaxant action on CCh-induced contraction of the tracheal smooth muscle, and that this sustained action is, at least in part, due to much lower susceptibility of the analog to degradation by peptidases, implying an advantage of the analog in clin. application.

CC 2-5 (Mammalian Hormones)

IT 176785-24-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained relaxant action of PACAP-27 analog on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro)

IT 176785-24-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(sustained relaxant action of PACAP-27 analog on carbachol-induced contraction of guinea pig tracheal smooth muscle in vitro)

RN 176785-24-3 CAPLUS


CN L-Leucinamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E

— Bu-i

— NH₂

REFERENCE COUNT:

18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997.154810 CAPLUS Full-text

DOCUMENT NUMBER: 126.152812

TITLE: Peptide bronchodilators

INVENTOR(S): Kashimoto, Kazuhisa; Nagano, Yumiko

PATENT ASSIGNEE(S): Itcham Foods Inc, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08333276	A	19961217	JP 1995-143581	19950609
CA 2196308	A1	19961227	CA 1996-2196308	19960606
CA 2196308	C	20001017		
WO 9641814	A1	19961227	WO 1996-JP1543	19960606
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, ER, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9659112	A	19970109	AU 1996-59112	19960606
AU 682638	B2	19971009		
EP 796867	A1	19970924	EP 1996-916331	19960606

10/536880

EP 796867 B1 20031105
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 CN 1161043 A 19971001 CN 1996-190882 19960606
 CN 1124283 B 20031015 19960606
 AT 253590 T 20031115 US 1996-916331 19970207
 US 5856303 A 19990105 JP 1997-776815 A 19950609
 JP 1995-143581 A 19951002
 JP 1995-253370 W 19960606
 WO 1996-JP1543

PRIORITY APPLN. INFO.:

AB The human pituitary adenylate cyclase-activating peptides and their pharmaceutical acceptable salts are claimed as bronchodilators. Thus 15 peptides were prepared, and their bronchodilator actions were tested in isolated guinea pig bronchial smooth muscle.

IC ICM A61K038-22

ICS C07K014-575

CC 1-9 (Pharmacology)

Section cross-reference(s): 34

IT 176785-24-3P 176785-25-4P 186253-19-0P 186322-91-8P

186767-50-0P 186767-52-2P 186767-54-4P

186767-56-8P 186767-60-2P 186767-62-4P 186767-64-6P 186844-11-1P

186844-12-2P 186844-13-3P 186844-14-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide bronchodilators)

IT 176785-24-3P 186767-50-0P 186767-52-2P

186767-54-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(peptide bronchodilators)

RN 176785-24-3 CAPLUS

CN L-leucinamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




10/536880


PAGE 1-B



PAGE 1-C



PAGE 1-D



10/536880


PAGE 1-E




RN 186767-50-0 CAPLUS
CN Glycinamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




10/536880


PAGE 1-C



PAGE 1-D



PAGE 1-E




RN 186767-52-2 CAPLUS
CN L-Lysinamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/536880

PAGE 1-A




10/536880


PAGE 1-D




PAGE 1-B



PAGE 1-E



PAGE 1-C




RN 186767-54-4 CAPLUS

CN L-Argininamide, L-histidyl-L-seryl-L-α-aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-valyl-L-leucylglycyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



111

112



L34 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:103361 CAPLUS Full-text
 DOCUMENT NUMBER: 126:181466

TITLE: Structure-activity relationship studies of PACAP-27 and VIP analogs

AUTHOR(S): Kashimoto, K.; Nagano, Y.; Suitani, Y.; Hamaoka, K.; Mizumoto, T.; Tomizaki, K.; Takahata, H.; Nagamoto, A.; Ohata, A.; et al.

CORPORATE SOURCE: Itoham Foods Inc. Central Research Institute, Ibaraki, 302-01, Japan

SOURCE: Annals of the New York Academy of Sciences (1996), 805(VIP, PACAP, and Related Peptides), 505-510
 CODEN: ANYA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To study the role of basic amino acid residues, PACAP-27 and VIP analogs were prepared and their biol. activity was measured. Their is a relationship between the duration of activity in preventing carbachol-induced bronchoconstriction in guinea pigs and the basicity of the peptides.

CC 2-2 (Mammalian Hormones)

IT 40077-57-4, Vasoactive intestinal octacosapeptide (pig) 127317-03-7,
 Human PACAP-27 147262-52-0 176785-24-3 176785-25-4
 186844-13-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationship studies of PACAP-27 and VIP analogs)



IT 176785-24-3





RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationship studies of PACAP-27 and VIP analogs)

RN 176785-24-3 CAPLUS

CN L-leucinamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-arginyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:286008 CAPLUS Full-text

DOCUMENT NUMBER: 124:331662

TITLE: Structure-activity relationship studies of PACAP-27

and VIP analogs

AUTHOR(S):

Kashimoto, Kazuhisa; Nagano, Yumiko; Suitani, Yoshihiko; Hamanaka, Kazuya; Mizumoto, Takahiro; Tomizaki, Kin-ya; Takahata, Hikari; Nagamoto, Akiko; Ohata, Akiko; et al.

CORPORATE SOURCE:

ItoHam Foods INC, Central Research Institute, Ibaraki, 302-01, Japan

SOURCE:

Peptide Chemistry (1996), Volume Date 1995, 33rd, 361-364

CODEN: PECHDP; ISSN: 0388-3698

PUBLISHER:

Protein Research Foundation

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB We obtained the results that the duration of tracheal relaxant activity varied with modification of PACAP-27 and VIP mols. The degree of the duration of activities was BM-analog > M-analog > native compound. These results show that there is a relation between the duration of activity and basicity of peptide caused by the number of basic amino acid residues in the sequence.

CC 1-3 (Pharmacology)

IT 37221-79-7, VIP 128606-20-2, Peptide PACAP 38 129069-75-6, Peptide

PACAP 27 176785-24-3 176785-25-4 176785-26-5 176897-83-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(structure-activity relationship studies of PACAP-27 and VIP analogs)


10/536880

10/536880


IT 176785-24-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-activity relationship studies of PACAP-27 and VIP analogs)
 RN 176785-24-3 CAPLUS
 CN L-leucinamide, L-histidyl-L-seryl-L- α -aspartylglycyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L- α -aspartyl-L-seryl-L-tyrosyl-L-seryl-L-arginyl-L-tyrosyl-L-tyrosyl-L-arginyl-L-glutamyl-L-leucyl-L-alanyl-L-valyl-L-arginyl-L-arginyl-L-arginyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 1-E

— Bu-i

— NH2

10/536880

--d his full

(FILE 'HOME' ENTERED AT 10:20:09 ON 30 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:20:41 ON 30 JAN 2007
369 SEA ABB=ON PLU=ON HSDA(IV)FT(IDEA) [SND]Y[ST]R[YL]R[QLAVRRY]LAA/
SQSPF

FILE 'CAPLUS' ENTERED AT 10:24:06 ON 30 JAN 2007
349 SEA ABB=ON PLU=ON L1

FILE 'REGISTRY' ENTERED AT 10:24:18 ON 30 JAN 2007
E A/NTE

113096 SEA ABB=ON PLU=ON AMI?/NTE

130 SEA ABB=ON PLU=ON L1 AND L3

FILE 'CAPLUS' ENTERED AT 10:26:18 ON 30 JAN 2007
266 SEA ABB=ON PLU=ON L4

FILE 'REGISTRY' ENTERED AT 10:26:42 ON 30 JAN 2007
54 SEA ABB=ON PLU=ON HSDA(IV)FT(IDEA) [SND]Y[ST]R[YL]R[QLAVRRY]LAA/
SQSP

FILE 'CAPLUS' ENTERED AT 10:29:23 ON 30 JAN 2007
4 SEA ABB=ON PLU=ON L6

FILE 'REGISTRY' ENTERED AT 10:30:11 ON 30 JAN 2007
30 SEA ABB=ON PLU=ON L6 AND L3

FILE 'CAPLUS' ENTERED AT 10:30:24 ON 30 JAN 2007
4 SEA ABB=ON PLU=ON L8

FILE 'REGISTRY' ENTERED AT 10:30:32 ON 30 JAN 2007

FILE 'STNGUIDE' ENTERED AT 10:31:59 ON 30 JAN 2007

FILE 'REGISTRY' ENTERED AT 12:08:18 ON 30 JAN 2007
STRUCTURE UPLOADED
0 SEA SSS SAM L10

FILE 'CAPLUS' ENTERED AT 12:09:29 ON 30 JAN 2007
E US2005-536880 /APPS
1 SEA ABB=ON PLU=ON US2005-536880 /AP
D SCA
SEL RN

FILE 'REGISTRY' ENTERED AT 12:09:52 ON 30 JAN 2007
36 SEA ABB=ON PLU=ON (127317-03-7/BI OR 134582-08-4/BI OR
137061-48-4/BI OR 37221-79-7/BI OR 40077-57-4/BI OR 475083-13-7
/BI OR 700368-76-9/BI OR 700368-79-2/BI OR 700368-81-6/BI OR
700368-83-8/BI OR 700368-85-0/BI OR 700368-87-2/BI OR 700368-90
-7/BI OR 700368-92-9/BI OR 700368-94-1/BI OR 700368-96-3/BI OR
700368-98-5/BI OR 700369-00-2/BI OR 700369-02-4/BI OR 702686-30
-4/BI OR 702686-31-5/BI OR 702686-33-7/BI OR 702686-36-0/BI OR
702686-37-1/BI OR 702686-38-2/BI OR 702686-42-8/BI OR 702686-49
-5/BI OR 702686-52-0/BI OR 702686-53-1/BI OR 702686-55-3/BI OR
702686-56-4/BI OR 702686-57-5/BI OR 702686-58-6/BI OR 702686-59
-7/BI OR 703414-61-3/BI OR 735327-72-7/BI)

119

10/536880

0 SEA SUB=L13 SSS SAM L10
11 SEA SSS FUL L10
SAVE TEMP L15 HA880STR10L/A

FILE 'CAPLUS' ENTERED AT 12:11:48 ON 30 JAN 2007
9 SEA ABB=ON PLU=ON L15
1 SEA ABB=ON PLU=ON L16 AND L12
9 SEA ABB=ON PLU=ON L9 OR L16
2952 SEA ABB=ON PLU=ON MATSUMOTO A7/AU
4255 SEA ABB=ON PLU=ON ENDO K7/AU
118 SEA ABB=ON PLU=ON ONQUE S7/AU
13 SEA ABB=ON PLU=ON L19 AND (L20 OR L21)
16 SEA ABB=ON PLU=ON L20 AND L21
23 SEA ABB=ON PLU=ON (L22 OR L23)
3 SEA ABB=ON PLU=ON (L19 OR L20 OR L21) AND (L16 OR L9)

FILE 'REGISTRY' ENTERED AT 12:14:39 ON 30 JAN 2007
62 SEA ABB=ON PLU=ON L6 OR L15
ANALYZE PLU=ON L26 1- LC : 4 TERMS
D

FILE 'TOXCENTER' ENTERED AT 12:15:18 ON 30 JAN 2007
1 SEA ABB=ON PLU=ON L26
20 SEA ABB=ON PLU=ON (L22 OR L23)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:15:53 ON 30 JAN 2007
42 SEA ABB=ON PLU=ON L24
20 DUP REM L30 (22 DUPLICATES REMOVED)
ANSWERS '1-12' FROM FILE MEDLINE
ANSWER '13' FROM FILE EMBASE
ANSWERS '14-20' FROM FILE BIOSIS

FILE 'STNGUIDE' ENTERED AT 12:16:16 ON 30 JAN 2007
D COST

FILE 'REGISTRY' ENTERED AT 12:18:30 ON 30 JAN 2007
D L8 RN CN SQL NTE LC KWIC 1-30

FILE 'CAPLUS' ENTERED AT 12:21:11 ON 30 JAN 2007
D STAT QUE L24
D STAT QUE L25
25 SEA ABB=ON PLU=ON (L24 OR L25)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:21:41 ON 30 JAN 2007
D STAT QUE L30

FILE 'TOXCENTER' ENTERED AT 12:21:53 ON 30 JAN 2007
D STAT QUE L29

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, TOXCENTER' ENTERED AT 12:22:17 ON
30 JAN 2007
32 DUP REM L32 L30 L29 (55 DUPLICATES REMOVED)
ANSWERS '1-25' FROM FILE CAPLUS
ANSWER '26' FROM FILE MEDLINE
ANSWERS '27-32' FROM FILE BIOSIS
D IBIB ABS HITIND HITSTR L33 1-25
D IALL L33 26-32

FILE 'REGISTRY' ENTERED AT 12:24:03 ON 30 JAN 2007

120

10/536880

FILE 'CAPLUS' ENTERED AT 12:24:08 ON 30 JAN 2007
D STAT QUE L9
D STAT QUE L16
6 SEA ABB=ON PLU=ON (L9 OR L16) NOT L32
L34
FILE 'TOXCENTER' ENTERED AT 12:24:42 ON 30 JAN 2007
D STAT QUE L28
0 SEA ABB=ON PLU=ON L28 NOT L29
L35
FILE 'CAPLUS' ENTERED AT 12:25:57 ON 30 JAN 2007
D IBIB ABS HITIND HITSTR L34 1-6
FILE 'TOXCENTER' ENTERED AT 12:25:59 ON 30 JAN 2007

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1
DICTIONARY FILE UPDATES: 29 JAN 2007 HIGHEST RN 918776-45-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JUNE 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprobs.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 29 Jan 2007 (20070129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.

10/536880

LAST RELOADED: Jan 26, 2007 (20070126/UP).

FILE TOXCENTER

FILE COVERS 1907 TO 23 Jan 2007 (20070123/ED)

This file contains CAS Registry Numbers for easy and accurate substance
identification.

The MEDLINE file segment has been updated with 2007 MESH terms and
See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MESH 2007 vocabulary.

FILE MEDLINE

FILE LAST UPDATED: 27 Jan 2007 (20070127/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been
added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R))
and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE EMBASE

FILE COVERS 1974 TO 30 Jan 2007 (20070130/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default)
and biweekly.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNE) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 January 2007 (20070124/ED)

=>